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Summary 
 
The aim of this study was to investigate practical methods of monitoring AIDS related 
wasting and lipodystrophy in a resource-poor clinical setting with HIV infected women as 
the population group of interest.  Measurement of body composition changes using 
anthropometry is both cost- and time-efficient.  Various different skinfolds were taken and 
two different equations (the equations of Pollock et al. (1975) and Durnin and Womersley 
(1974) for calculating body fat were used to determine the most promising method or 
methods of monitoring body composition changes in a clinical setting.   
 
Detailed anthropometric measurements were performed, as well as selected measurements 
for haematological parameters and quality of life (QoL) for a group of 8 participants on 
antiretroviral medication (ART group) and 6 participants who were not on treatment (TN 
group).  New variables namely, intra-abdominal indicator (IAI) and a percent of ideal body 
mass to percent of ideal arm circumference ratio (%IBW:%IAC) were investigated as 
possible indicators of lipodystrophy.  Although measurements were taken at various time-
points, three specific time-points were chosen for data-analysis for the ART group and two 
time points for the TN group.  These three time-points were, baseline (on the day of 
recruitment for TN participants and within one month before the initiation of treatment for 
ART participants), short-term (2 to 12 weeks after treatment initiation or the baseline 
measurement or for the ART and the TN participants) and long-term (within one and a half 
year of treatment initiation for the ART group).   
 
ART and TN participants did not differ for many variables at baseline.  The major 
differences between ART and TN were in measured and derived variables of the arm, 
especially percent of ideal arm circumference (%IAC) and upper arm fat area (UAFA), 
which were significantly lower in the ART group.   
 
CD4+ and QoL improved significantly for the ART participants from baseline to long-term.  
This was not associated with changes in muscle mass, but rather some fat mass variables.  
Participants on antiretroviral medication exhibited changes relating to abdominal obesity.  
It was concluded that antiretroviral therapy contributed greatly to the QoL of the 
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participants and it probably aided in the recovery from wasting for at least one participant 
in this study.  Measures of the arm can be used in a rural clinical setting to effectively 
monitor patients with regard to AIDS related wasting.  The new variables IAI and 
%IBW:%IAC could be helpful in the monitoring of lipodystrophy and should be 
investigated in future research. 
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Opsomming 
 
Die doelwit van hierdie studie is om praktiese metodes te ondersoek om VIGS-verwante 
uittering en lipodistrofie te meet in ‘n plattelandse kliniese omgewing (waar hulpbronne 
dikwels beperk is) met MIV ge-infekteerde vroue as populasiegroep. Die gebruik van 
antropometrie om veranderinge in liggaamssamestelling te meet is beide koste- en 
tydeffektief.  Verskeie velvoumetings is geneem en twee verskillende vergelykings (die 
vergelykings van Pollock et al. (1975) en Durnin en Womersley (1974)) is gebruik om 
liggaamsvetinhoud te bereken, met die doel om ‘n belowende metode te vind om 
veranderinge in liggaamssamestelling te meet in ‘n kliniese omgewing. 
 
Verskeie antropometriese metings is geneem, sowel as uitgesoekte hematologiese en 
lewenskwaliteitmetings (QoL) vir ‘n groep van agt deelnemers wat antiretrovirale 
medikasie ontvang het (ART groep) en ses deelnemers wat nie hierdie behandeling ontvang 
het nie (TN groep).  Nuwe veranderlikes (binnebuikindikator (IAI) en die verhouding van 
persentasie van ideale liggaamsmassa tot persentasie van ideale armomtrek 
(%IBW:%IAC)) is ondersoek as moontlike aanwysers van lipodistrofie.  Drie spesifieke 
tydpunte vir die ART groep en twee tydpunte vir die TN groep is gekies uit die verskeie 
tydpunte waarby metings geneem is, nl. basislyn (gedefinieer as die dag wat TN deelnemers 
in die studie opgeneem is en 0 tot 4 weke voor die begin van behandeling vir die ART 
deelnemers), korttermyn (2 tot 12 weke nadat behandeling begin is of na die basislyn 
meting) en lang-termyn (binne een en ‘n half jaar nadat behandeling begin is vir die ART 
groep).   
 
By die basislyn tydpunt het min van die ART en TN deelnemers se gemete veranderlikes 
verskil. Die ART en TN groepe het hoofsaaklik verskil ten opsigte van veranderlikes wat 
betrekking het op die arm, veral persentasie van ideale armomtrek (%IAC) en bo-arm vet-
area (UAFA).  Hierdie twee veranderlikes was beduidend laer in die ART groep as in die 
TN groep.   
 
CD4+ seltelling en lewenskwaliteit tellings het beduidend verbeter vir die ART deelnemers 
van die basislyn tot die lang-termyn tydpunt.  Hierdie veranderinge is nie samehangend met 
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veranderinge in spiermassa nie, maar eerder met sommige vetmassa veranderlikes.  
Deelnemers wat antiretrovirale medikasie ontvang het, het veranderinge getoon wat gedui 
het op ‘n verhoogde neerlegging van vet in die buikarea.  Ten slotte is bevind dat 
antiretrovirale medikasie bygedra het tot die verbeterde lewenskwaliteit van die deelnemers 
en dat dit waarskynlik ook die omkeer van uittering van ten minste een deelnemer 
aangehelp het.  Daar is ook bevind dat armverwante metinge gebruik kan word in die 
plattelandse kliniese omgewing om pasiënte suksesvol te monitor ten opsigte van VIGS-
verwante uittering.  Die nuwe veranderlikes, IAI en %IBW:%IAC kan moontlik gebruik 
word om lipodistrofie-verwante veranderings te meet en die gebruik van hierdie 
veranderlikes behoort ondersoek te word in verdere navorsing. 
Stellenbosch University http://scholar.sun.ac.za
 7
Acknowledgements  
 
I would like to give special thanks to everyone in the department who helped me with 
advice and assistance (especially those who volunteered to be subjected to measurements 
and interviews while I was practicing data gathering techniques, as well as those who 
assisted from time to time in data gathering in the department and at the clinics). 
 
I also wish to express sincerest gratitude towards everyone at Paarl HIV-clinic. I have great 
admiration for what you achieve there and I wish you the best for the future.  Thank you Dr 
Grobbelaar for seeing opportunities where others see problems. 
 
I am most grateful for the knowledge and advice of Drs. Smith and Nell and especially, 
Prof. Myburgh, without whom this project would have been impossible. 
 
Deepest thanks also to Pieter, my family and friends for their endless patience and support.   
 
Stellenbosch University http://scholar.sun.ac.za
 8
Abbreviations 
 
%IAC Percentage of ideal arm circumference 
%IBW Percentage of ideal body mass 
AIDS Acquired immune deficiency syndrome 
AWS AIDS wasting syndrome 
BCM Body cell mass 
BIA Bioelectric impedance analysis 
BM Body mass1 
BMI Body mass index (body mass (kg) / height2 (m2)) 
BW2 Body mass  
BWL2 Body mass loss 
%CD4  CD4+ count as a percent of total lymphocyte count  
CNS Central nervous system 
D Body density (g/mL) 
DHEAS Dehydroepiandrosterone-sulphate 
DHHS Department of Health and Human Services 
DW Refers to the equations of Durnin and Womersley (1974) 
DXA dual X-ray absorptiometry 
ECM Extracellular mass 
ECW Extracellular water 
Fat% Fat percentage 
FDA Food and drug administration (United States of America) 
FFM Fat free mass 
FM Fat mass 
GI Gastro-intestinal 
                                                 
1 Also referred to as body weight in some anthropometric calculations and tables. 
2 Accepted abbreviation for “mass” in anthropometry is “W” except for body mass index, hence abbreviations 
reflect common use in the literature (E.g. Kotler et al., 1989; Melchior et al., 1999; Nemechek et al., 2000). 
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HAART Highly active antiretroviral therapy 
HDL High density lipoprotein 
HIV Human immunodeficiency virus 
IAC Ideal arm circumference 
IAF Intra-abdominal fat 
IAI Intra-abdominal indicator 
IAI:H Intra-abdominal indicator to hip ratio 
IBW Ideal body mass 
ICW Intracellular water 
IL-6 Interleukin-6 
Pol Refers to the equations of Pollock et al. (1975) 
LBM Lean body mass 
LBMI Lean body mass index (lean body mass (kg) / height2 (m2))  
LDL Low density lipoprotein 
MRI Magnetic resonance imaging 
mtDNA Mitochondrial deoxyribonucleic acid 
NNRTI Non-nucleoside reverse transcriptase inhibitor 
NRTI Nucleoside reverse transcriptase inhibitor 
nSREBP Nuclear sterol regulatory element binding proteins 
PCM Protein-calorie malnutrition 
PI Protease inhibitor 
QoL Quality of life 
SCF Subcutaneous fat 
SKF Skinfold thickness or skinfold thickness analysis 
TB The disease tuberculosis which is caused by Mycobacterium tuberculosis 
TBK Total body potassium 
TBW Total body water 
TI Treatment initiation 
TN Treatment naïve 
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TNF Tumour necrosis factor 
UAC Upper arm circumference, also known as mid upper arm circumference (MUAC) 
UAFA Upper arm fat area 
UAMA Upper arm muscle area 
W:H Waist to hip ratio 
WHO World Health Organisation 
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1. Introduction 
 
Untreated infection with the human immunodeficiency virus (HIV) leads to severe physical 
debilitation and disease culminating in the acquired immune deficiency syndrome (AIDS) 
and eventually, death.  A joint report by the United Nations Programme on HIV/AIDS 
(UNAIDS) and the World Health Organization (WHO) stated that an estimated 39.4 
million people worldwide were living with HIV in 2004.  An estimated 3.1 million deaths 
as a result of AIDS were also reported for 2004.  Most of the people living with HIV are 
residents of Sub-Saharan Africa and numbered an estimated 25.4 million people in 2004.  
Compared to the next area of highest infection (South and South-East Asia with 7.1 million 
people living with HIV) this is indeed an astoundingly high prevalence.  HIV/AIDS has 
become the largest cause of death in South Africa (Baleta, 2005). 
 
The UNAIDS & WHO also reported that 57% of the people living with HIV in Sub-
Saharan Africa were women (2004).  Many factors were mentioned that could lead to an 
increased infection rate for women in this area.  Social inequalities (accentuated by a lesser 
availability of education and lower social status for women), impoverishment, social 
distortions brought about by the migrant labour systems, intimate partner violence as well 
as a greater risk of infection in young women compared to men increase the vulnerability of 
women to becoming infected. 
 
Furthermore, the whole society is affected by the high infection rate of women since they 
are often the main caregivers in the communities of Sub-Saharan African countries.  The 
UNAIDS & WHO report stated that in South Africa, almost three quarters of AIDS 
affected households were headed by females, frequently with AIDS-related illnesses 
themselves.  Illness and weakness result in a cycle of poverty and misfortune, impacting on 
a social as well as an economic level.  Although, the situation was further aggravated by an 
absence of public access to antiretroviral drugs, these have become available at selected 
clinics in South Africa since 2004 (Baleta, 2003). 
 
Therefore, it is important to investigate HIV infected women and the impact of 
antiretroviral treatment on this population in South Africa from multiple perspectives.  
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AIDS related wasting and lipodystrophy are two conditions that should be assessed. 
Monitoring could be done by appropriately trained exercise physiologists since information 
gained could potentially lead medical practitioners to recommend lifestyle changes.  The 
aim of this study was to investigate practical methods of monitoring these two conditions in 
a resource-poor clinical setting with HIV infected women as the population group of 
interest.  The criteria that were considered to define a practical method of measuring body 
composition changes in such a setting were that it should be cost- and time-efficient.  
Determining body composition using anthropometry may be a practical way of 
investigating changes in body composition related to wasting and lipodystrophy.  A 
comprehensive battery of skinfold thicknesses were measured, along with various 
circumference measurements to determine the most promising subset for monitoring body 
composition changes in a clinical setting.   
 
The literature review for this study is preceded by a general introduction to the disease 
progression and treatment of an HIV infection.  Thereafter, AIDS related wasting, 
lipodystrophy, quality-of-life and methods of monitoring body composition are the focus 
points of the literature review. 
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2. Background to HIV/AIDS and ART 
 
The following general introduction to the disease and the treatment thereof is important 
when considering disease progression and the impact of antiretroviral treatment on the 
study population. 
 
2.1 Clinical aspects of HIV/AIDS 
 
Acquired immune deficiency syndrome (AIDS) first emerged in 1981 in America as well as 
in Africa (Hooper, 2000).  The virus that caused AIDS was isolated in 1983.  Although it 
was initially referred to as the lymphadenopathy associated virus (LAV) or human T-
lymphotropic virus III (HTLV-III), it was eventually named the human immunodeficiency 
virus (HIV) (Weatherall et al., 1996). 
 
2.1.1 The disease 
 
HIV is a retrovirus of the lentivirus family, which is a subfamily of retroviruses.  
Retroviruses possess the unique ability to copy their viral RNA genome into strands of 
DNA using the reverse transcriptase enzyme.  Based on genome organization and 
phylogenetic relationships, the virus can be divided into two types (HIV-1 and HIV-2) and 
subdivided into numerous subtypes (Janse van Rensburg, 2000).  HIV-1 infection is the 
most prevalent, as HIV-2 infections are, for the most part, only found in West Africa 
(Weatherall et al., 1996). 
 
Transmission of the virus can occur as a result of sexual intercourse, direct blood-to-blood 
contact and through the use of contaminated needles.  An infected mother can also pass the 
virus on to her infant through breastfeeding and during birth.  The virus resides in CD4+ 
lymphocytes and is therefore transmitted from person to person via these cells. 
 
Cluster of differentiation (CD) refers to markers that bind to specific polypeptides on 
immune and some other cells (Roitt & Rabson, 2000).  Therefore the CD4 marker indicates 
that cell-surface CD4 molecules are present.  CD4 molecules are abundant on helper T-
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cells, but macrophages and microglia also have low densities of these molecules on their 
surfaces (Roitt & Rabson, 2000).   
 
The HIV glycoprotein, gp 120, binds to CD4 molecules when infecting a cell.  After co-
receptor binding and fusion of the viral membrane with the cell membrane, the virus enters 
the cell.  The viral RNA is then converted to the corresponding DNA via reverse 
transcriptase.  This DNA is integrated into the host genome where it can remain latent or be 
transcribed when the host cell is activated by cytokines or an antigen (Roitt & Rabson, 
2000). 
 
The progression of HIV infection can be divided into three stages.  A primary viraemia 
develops four to eight weeks after infection and the virus is dispersed throughout the body 
during this stage (Weatherall et al., 1996).  This stage is associated with an immune 
response that typically produces cytotoxic T-cells and antibodies to the envelope proteins 
gp 120 and gp 41 and especially the nucleocapsid HIV protein p24 (Roitt & Rabson, 2000).  
The second stage is characterized by low viraemia as the HIV particles are mostly confined 
to lymphoid tissue.  The person can be asymptomatic, or have only minor symptoms of 
infection.  Generally, there is a gradual decrease in CD4+ T-cells during the asymptomatic 
period.  The duration of this period is highly variable, but it can last up to twelve years 
(Weatherall et al., 1996). 
 
The cause of the drop in CD4+ T-cells cannot be fully explained.  Although the HIV kills 
the cell directly once viral replication reaches high levels – some other factor (or factors) 
are thought to contribute to the decline of CD4+ cells.   Various hypotheses have been 
proposed, including the inhibition of new T-cell production, increased cytotoxic CD8+ cells 
which play a role in the lysing of infected CD4+ cells, an increased susceptibility to 
apoptosis and changes in the viral phenotype expression (Ribeiro et al., 2006; Roitt & 
Rabson, 2000; Weatherall et al., 1996). 
 
Ultimately the falling number of CD4+ T-cells will predispose the individual to 
development of opportunistic infections and the person will enter the third stage of the 
disease.   If the disease is not treated, the person may only survive for about two to three 
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years with the “acquired immune deficiency syndrome” (AIDS), which will eventually 
result in death (Weatherall et al., 1996). 
 
Depending upon the geographical area, different definitions of AIDS are used (see 
Appendix A, Section 1).  In developed countries a person will be diagnosed with AIDS if 
he or she has a proven HIV infection and a CD4+ lymphocyte count less than 200 per μl 
irrespective of clinical manifestation (Weatherall et al., 1996).  In developing countries, 
where laboratory resources may be limited, other indicator diseases are used to diagnose 
AIDS. 
 
Two staging systems to assist physicians in the assessment of their patients have been 
independently published by the WHO and the U.S. Centers for Disease Control (CDC).  A 
1989 version of the WHO classification system, shown in Table 1, describes 3 groups (A – 
C) based on laboratory measurements, co-classified into 1 of 4 groups (A1 – A4; B1 – B4; 
C1 – C4) based on clinical symptoms (Weatherall et al., 1996).   
 
In contrast, the 1993 version of the CDC classification system categorises the condition of a 
patient according to disease stage into one of three clinical categories (A indicates early 
disease, B late disease and C advanced disease).  The CD4+ count of the individual is also 
used to specify an immune category (category 1 represents a CD4+ count of 500 cells/μL or 
more, category 2 represents a CD4+ count of 200 cells/μL or more, but less than 500 
cells/μL and category 3 signifies CD4+ counts less than 200 cells/μL) providing information 
about the disease progression.  The lowest recorded CD4+ count is used and a lower 
category cannot be reassigned if the patient’s CD4+ count increases (Baylor College of 
Medicine, 2003).  
 
This CDC classification system is clearly very similar to the WHO system, although it may 
be confusing since the numbering and lettering allocation is reversed.  Letters A to C 
indicate a classification based upon haematological data and numbers are used to classify a 
person into a clinical group according to the WHO system, while the CDC classification 
system uses A to C to indicate disease stage and CD4+ categories are given a number from 
1 to 3. 
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Table 1:  The WHO classification system for HIV infection (rewritten from Weatherall et 
al., 1996). 
Laboratory group Clinical group 
 Lymphocyte count (x106/l) CD4+ count (x106/l) 1 2 3 4 
A > 2 000 > 500 1A 2A 3A 4A 
B 1 000 – 2 000 200 – 500 1B 2B 3B 4B 
C < 1 000 < 200 1C 2C 3C 4C 
Clinical group 1: 
Clinical group 1 of the WHO staging system represents those HIV-infected people who 
are asymptomatic or only have persistent generalized lymphadenopathy.  They can also 
participate in normal physical activities.   
Clinical group 2: 
Clinical group 2 represents the early stage disease when the person becomes symptomatic 
(but still retains normal physical activity) and body mass loss of less than 10 percent of 
body mass becomes apparent. Symptoms include recurrent upper respiratory tract 
infections and herpes zoster (shingles) infection occurring within 5 years.    
Clinical group 3: 
A person will be classified with intermediate stage disease (group 3) when one or more of 
the following has occurred: a body mass loss of more than 10 percent of body mass, 
unexplained chronic diarrhoea for more than one month, unexplained prolonged fever for 
more than 1 month, oral candidiasis, oral hairy leucoplakia, pulmonary tuberculosis 
within 1 year, severe bacterial infections and/or being bedridden less than 50 percent of 
the day during the previous month.   
Clinical group 4: 
A person will be classified with late stage disease when diagnosed with any of the AIDS-
defining illnesses (as specified by die CDC – see appendix A, section 1) and/or this 
person has been bedridden for more than 50 percent of the day during the previous month.  
 
Of particular relevance to the current study are the facts that multiple infections, physical 
weakness, body mass loss and wasting are characteristic manifestations of the disease (see 
Table 1) and impact on the affected person’s ability to lead a productive life.  Poverty and 
limited access to resources may contribute to these manifestations and complicate the 
treatment choices thereof especially in the rural and semi-rural areas of South Africa.  
Clearly it is a debilitating disease and even though antiretroviral medicine has improved the 
quality of life of people suffering from the disease, the medicine itself may also impact 
negatively on the body composition of treated patients. 
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2.1.2 Antiretroviral medicine 
 
At present there is no cure for an HIV infection and the design and testing of an effective 
vaccine is proving to be a time-consuming challenge.  The main goal of current 
antiretroviral treatment (ART) is to reduce viral replication and levels (viral load) in the 
blood to allow the immune system to regain some of its lost function (Baylor College of 
Medicine, 2003).  Therefore, one of the primary outcomes of ART is a reduced frequency 
of opportunistic infections and a general improvement in health.  Antiretroviral therapy has 
prolonged the life expectancy of countless HIV-infected patients and consequently there are 
many living relatively normal lives with HIV and AIDS.   
 
Although ART is generally effective in reducing viral load and improving health, there are 
many drawbacks to the treatment.  The medicine has to be taken regularly for the rest of the 
HIV-infected individual’s life and the patient who doesn’t comply with a strict drug-taking 
regimen may potentially experience drug-resistance and treatment failure.  Rigorous 
adherence to ART is therefore essential.  Accessibility to water and food with which to take 
the medication, severe side-effects, multiple medications and interactions with other 
medicine are some of the additional obstacles that may influence adherence to treatment 
(Baylor College of Medicine, 2003).  
 
The first drug to be developed (in 1985) against the HIV was zidovudine (3’-azido-
3’deoxythymidine).  Yet, it was shown that treatment with zidovudine (also known as AZT, 
ACT and ZDV) as monotherapy is likely to lead to treatment failure due to the 
development of drug resistance.  Since the development of additional drugs (like 
didanosine (dideoxyinosine, ddI) and zalcitabine (dideoxycytidine, ddC)) the use of 
combination therapy has been explored and found to be quite effective (Weatherall et al., 
1996). 
 
At present, a host of different antiretroviral medicines are available.  They can be classed 
into three groups:  nucleoside reverse transcriptase (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs).  As shown in Figure 1, the 
Stellenbosch University http://scholar.sun.ac.za
 20
groups indicate at which stage of viral replication the medicine acts (Baylor College of 
Medicine, 2003). 
 
 
 
 
 
 
 
 
 
 
Figure 1:  The sites of action of common antiretroviral medication in relation to the life 
cycle of the HIV (reproduced exactly from Baylor College of Medicine, 2003). 
 
Either two or three different drugs are commonly used in combination therapy.  The use of 
three different drugs is referred to as highly active antiretroviral therapy (HAART).  
HAART is believed to be the most effective therapy to suppress viral replication, but two-
drug therapy has also been shown to increase survival and improve quality of life (QoL) 
(Baylor College of Medicine, 2003).  Any treatment regimen should consist of at least two 
nucleoside reverse transcriptase inhibitors (NRTIs).  One of these should be a thymidine 
analogue (such as d4T or ZDV), while the other should be a non-thymidine analogue (such 
as ddI, ddC or 3TC) (Baylor College of Medicine, 2003).  A protease inhibitor (PI) or non-
nucleoside reverse transcriptase inhibitor (NNRTI) can be added as the third drug (Baylor 
College of Medicine, 2003).  A three NRTI therapy (referred to as a triple nucleoside 
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regimen) can also be used (Baylor College of Medicine, 2003; WHO, 2004).  Table 2 
summarizes the currently available antiretroviral drugs with their possible side effects. 
 
Table 2a:  Antiretroviral medications and side effects (adapted from Baylor College of 
Medicine, 2003). 
Class Antiretroviral drug Possible side effects  
Didanosine (ddI); Videx 
Common:  nausea; vomiting; diarrhea; abdominal pain 
Severe:  Peripheral neuropathy; electrolyte abnormalities; 
hyperuricemia; lactic acidosis with hepatic steatosis 
Uncommon:  pancreatitis; increase liver function tests; retinal 
depigmentation 
 
Lamivudine (3TC); Epivir 
Common:  nausea; diarrhea; headache; fatigue; skin rash; abdominal 
pain 
Severe:  pancreatitis; lactic acidosis with hepatic steatosis 
 
Zalcitabine (ddC); Hivid 
Common:  headache, malaise 
Severe:  peripheral neuropathy; pancreatitis; hepatic toxicity; rash; oral 
ulcers; hematologic toxicity  
 
Zidovudine (ZDV); Retrovir Common:  hematologic toxicity; headache Other:  myopathy; myositis; liver toxicity 
 
Stavudine (d4T); Zerit 
Common:  headache; nausea; vomiting; diarrhoea; skin rash; increase 
liver function tests 
Severe:  peripheral neuropathy; pancreatitis; lactic acidosis with 
hepatic steatosis 
 
Abacavir; Ziagen 
Common:  nausea; vomiting; diarrhea; loss of appetite; malaise; 
headache; rash 
Severe:  hypersensitivity (do not rechallenge) 
 
Tenofovir; Disoproxil; 
Fumarate; Viread asthenia; headache; flatulence; nausea; lactic acidosis 
 
Zidovudine/Lamivudine; 
Combivir lactic acidosis with hepatic steatosis 
 
N
R
T
I 
Zidovudine/Lamivudine/ 
Abacavir; Trizivir lactic acidosis with hepatic steatosis 
 
Delavirdine (DLV); 
Rescriptor Common:  headache; fatigue; nausea, vomiting, diarrhoea; rash 
 
Nevirapine (NVP); Viramune Common:  rash; sedative effects; headache; nausea; diarrhoea Other:  increase liver function tests; rare-hepatitis 
 
N
N
R
T
I 
Efavirenz Common:  rash; central nervous system (dizziness, etc) Other:  increase liver function tests 
 
 
In South Africa, Stavudine, Lamivudine and Efavirenz (kown as Stocrin in South Africa) 
are used as the first line of treatment, whereas Didanosine, Zidovudine and Combivir are 
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used in cases of treatment failure (insufficient viral suppression despite compliance) or 
other reason to alter treatment (e.g. lactic acidosis). 
 
As shown in Tables 2a and 2b, an extensive range of side effects is associated with ART.  
Although some side effects like headache and nausea may only be experienced with the 
initiation of therapy, others can lead to toxicity.  Side effects that persist and are not well 
tolerated can result in significant organ dysfunction related to toxicity (WHO, 2004).  
Toxicities observed in treated patients include neuropathy, pancreatitis, lipoatrophy, 
hepatotoxicity, severe but not life-threatening rash, life-threatening rash, persistent gastro-
intestinal (GI) intolerance, lactic acidosis, haematological toxicity, mitochondrial toxicity, 
myopathy, muscle wasting, anaemia and persistent central nervous system (CNS) toxicity 
(WHO, 2004; Baylor College of Medicine, 2003; Yarasheski & Roubenoff, 2001). 
 
Table 2b:  Antiretroviral medications and side effects (adapted from Baylor College of 
Medicine, 2003). 
Class Antiretroviral drug Possible side effects 
Indinavir (IDV); Crixivan 
Common:  nausea; abdominal pain; headache; asymptomatic 
hyperbilirubinemia 
Severe:  nephrolithiasis 
Other:  spontaneous bleeding; hyperglycemia 
Nelfinavir (NFV); Viracept 
Common:  nausea; vomiting; diarrhoea; headache especially if receiving 
ZDV 
Other:  asthenia; abdominal pain; rash; hyperglycemia 
Saquinavir (SQV), hard 
gelatin capsules; Invirase  
Common:  nausea; vomiting; diarrhoea; abdominal pain; headache 
Other:  spontaneous bleeding; hyperglycemia 
Saquinavir (SQV); soft 
gelatin capsules; Fortovase 
Common:  nausea; vomiting; diarrhoea; abdominal pain; headache 
Other:  spontaneous bleeding; hyperglycemia 
Ritonavir (RTV); Norvir 
Common:  nausea; vomiting; diarrhoea; abdominal pain; anorexia 
Other:  circumoral paresthesias; increase liver function tests; spontaneous 
bleeding; pancreatitis; increase Triglyceride and Cholesterol; hyperglycemia
Lopinavir/ritonavir; Kaletra Common:  nausea; vomiting; diarrhoea, headache Other:  hyperglycemia; increase liver function tests 
PI
 
 Amprenavir; Agenerase Common:  headache; nausea; vomiting; diarrhoea; rash 
 
HAART seems to be particularly associated with toxicities.  Disturbances in lipid 
metabolism – leading to lipodystrophy, hyperlipidaemia, insulin resistance and 
hyperglycaemia – appear to be strongly associated with PI-based HAART (Calza et al., 
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2003; Hui, 2003).  However, PI-naïve patients treated with two NRTIs have also been 
shown to exhibit the same manifestations of a disrupted lipid metabolism (Galli et al., 
2002). 
 
Therefore, although ART is a life-saving intervention that may improve the quality of life 
and survival rate of infected patients, it carries with it a range of possible complications. 
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3. Literature review 
 
The following literature review will focus on changes in body composition (whole body or 
regional muscle mass and fat mass) that may occur in  HIV infected individuals.  The 
mechanisms behind these changes as well as possible treatment options that have been 
explored are presented.  The practicality of methods of monitoring these changes in a 
clinical setting is discussed.  These issues will be discussed taking into account the role that 
health care professionals (especially exercise physiologists) can play in this regard. 
 
3.1 Body composition changes with ART 
 
Since wasting is directly associated with HIV/AIDS disease progression (Kotler et al., 
1989), nutrition was initially the main concern of paramedical health care professionals 
working with infected patients.  The use of antiretroviral medications proved to be effective 
in reducing body mass loss and wasting (Dworkin et al., 2003).  However, it became 
apparent, as discussed in the previous section, that the toxic effects of HAART give rise to 
metabolic complications and lipid abnormalities.  Patients reported experiencing a loss of 
fat in the face, arms and legs (Brinkman et al., 1999; Carr et al., 1998).  Some would also 
experience a concomitant increase of waist circumference.  An increased deposition of 
intra-abdominal fat has been implicated for this increase in girth (Miller et al., 1998).  The 
accumulation of adipose tissue in areas like the dorso cervical region of the neck and the 
breasts in the form of unencapsulated lipomas (similar to Madelung’s syndrome) has also 
been observed with lipodystrophy (Salomon et al., 2002; Brinkman et al., 1999; Lo et al., 
1998).  Therefore, ART may improve wasting, but it may cause detrimental changes in fat 
deposition. 
 
3.1.1 The AIDS wasting syndrome (AWS) 
 
The HIV wasting syndrome is defined as involuntary body mass loss greater than 10% in 
addition to unexplained chronic diarrhoea for more than one month, or weakness and 
unexplained prolonged fever for more than one month (Baylor College of Medicine, 2003; 
Nemechek et al., 2000; CDC, 1993).  Other definitions of wasting that have been used are a 
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loss of more than 5% of body weight within six months with the loss sustained for more 
than a year and a body mass index that had fallen below 20 kg/m2 (Wanke et al., 2000). The 
HIV wasting syndrome is an AIDS defining condition (Baylor College of Medicine, 2003) 
and it is therefore also known as the AIDS wasting syndrome (AWS).  
 
Kotler, et al. (1989) showed that the magnitude of body cell mass (BCM) depletion is 
related to the timing of death from wasting in AIDS.  In this study, a regression line 
generated from the total body potassium (TBK) and anthropometric measurements of 43 
patients indicated that body mass at 100 days before death is 90% of ideal body mass, but 
TBK (normalized for height, age and sex) extrapolated to only 71% of normal at 100 days.  
Since most potassium in the body is found in the non-adipose tissue cell mass, a 
measurement of TBK represents mainly the non-adipose tissue cell mass of the body 
(BCM).  This study clearly demonstrated that a small perturbation in body mass can occur 
concomitantly with a greater change in BCM.  The study also provided evidence that a 
critical level of body cell mass is needed for survival.  If this pattern of wasting is typical of 
the AWS, it is clear that simply monitoring body mass is insufficient.  Melchior et al. 
(1999) found lean body mass index (LBMI = lean body mass (kg) / height2 (m2)), but not 
body mass loss, was an independent predictor of survival after controlling for other factors.  
Interventions that replete body cell mass are therefore critical for patients that suffer from 
the wasting syndrome. 
 
It has been shown that a body mass loss greater than 10% prior to AIDS is associated with 
an increased risk of death (Palenicek et al., 1995).  Even a body mass loss between 5% and 
10% has been shown to be associated with in increased risk of death and opportunistic 
complications (Wheeler et al., 1998).  Therefore, even slight body mass changes may be 
indicative of wasting.  Ott and colleagues (1993) have demonstrated that there may be signs 
of malnutrition in patients with HIV as evidenced by a significantly increased ECM 
(extracellular mass) and ECM to BCM ratio compared to a control group, while BMI and 
body mass appear to be unaffected.  The values of these variables are shown in Figure 2 for 
the HIV patient groups. 
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Figure 2:  Results of CD4+ cell count and body composition measurements of 
193 male HIV infected patients at various disease stages.  There were four 
patient groups, those with no diarrhoea (n = 114); mild diarrhoea (n = 42), mild 
to severe diarrhoea (n = 7) and those with severe or permanent diarrhoea (n = 
30).  P values are comparisons with the group of patients without diarrhoea 
(redrawn from Ott et al., 1993). 
 
The definition of wasting based on body mass is practical but may be too insensitive as 
patients with only a small body mass loss may actually be losing a greater amount of 
essential body mass.  Nemechek and colleagues (2000) suggested that additional 
measurements of body composition should also be made when assessing patients.  These 
authors suggested that body composition measurements should be made every 3 to 4 
months.  Bioelectric impedance analysis (BIA) and skinfold measurements were suggested 
as possible methods of measuring changes in body composition.  In a review, Salomon et 
al., (2002) also concluded that anthropometric measurements and BIA are practical 
solutions for measuring body composition changes in HIV patients.  These measurements 
can enable clinicians and other health care workers to follow changes in BCM closely and 
assess patients more accurately. 
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Within the context of trying to understand HIV/AIDS in Sub-Saharan Africa, a drawback of 
the above-mentioned studies is that most of the study participants were men.  Although the 
gender ratio of the cohort weren’t mentioned by Kotler and co-workers (1989) in their 
publication, 95% of the participants were men in the study conducted by Melchior and 
colleagues (1999).  Nevertheless, these two studies demonstrated the importance of 
considering LBM or BCM changes instead of BW when assessing the severity and impact 
of wasting.  The studies done by Macallan et al. (1993) and Palenicek et al. (1995) had only 
male participants, while only 7.1% of the Wheeler et al. (1998) study participants were 
female.  These three studies illustrated the importance of body mass loss and its relation to 
disease progression.   
 
In the first instance, it would be important to know whether the observations made in all of 
the above studies can be applied to a female population.  A decade after their ground-
breaking study, Kotler et al. (1999) indicated that women lose proportionately more fat 
than men during HIV infection.  Swanson et al. (2000) also presented evidence that 
suggested that HIV-infected women show a preferential loss of fat mass (FM) and a relative 
preservation of BCM.  The authors of both studies suggested that a higher initial body fat 
content may predispose individuals to lose relatively more fat than LBM during wasting.  
Alternatively, the opposite may be true for men or wasting may be influenced by the sex 
hormone environment. 
 
In addition, it would be important to know whether these observations apply to females in 
Sub-Saharan Africa where racial and socio-economic differences could influence disease 
progression and body composition changes. 
 
a. Mechanisms of wasting 
 
The underlying causes of the wasting process are often multiple.  It has been shown that 
opportunistic infections, chronic diarrhoea, decreased dietary energy intake and also 
increased resting energy expenditure (REE) are correlated with body mass loss (Melchior et 
al., 1999; Wheeler et al., 1998).  An altered metabolism, malabsorption of nutrients, 
increased cytokine levels, endocrine abnormalities and primary muscle disease have also 
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been implicated as possible underlying mechanisms of the wasting syndrome (Chang, et al. 
1997).  In a study that evaluated the deltoid muscle biopsy samples of 30 patients with the 
wasting syndrome (of which 26 were male), only 11 were found to have HIV-related 
myopathy (Miró et al., 1997).  The authors of this publication concluded that the AWS is a 
heterogeneous condition and not a true myopathy.  Some of the endocrine abnormalities 
that have been shown to be associated with HIV infection include elevated concentrations 
of resting cortisol (which can lead to increased amino-acid catabolism) and decreased 
concentrations of dehydroepiandrosterone sulphate (DHEAS) (Christeff et al. 2000; De La 
Torre et al. 1997).  While cortisol stimulates amino-acid catabolism, DHEA is anti-
catabolic. 
 
Cytokines may contribute to wasting and cachexia through various mechanisms (Chang et 
al., 1998).  In a review, Chang et al. (1998) stated that thyroid hormone and adrenal and 
gonadal homeostasis could be altered by cytokines during HIV infection, which may lead to 
hypermetabolism, anorexia and cachexia.  Cytokines could play a role in stimulating the 
ubiquitin-proteasome pathway causing muscle proteolysis.  Unfortunately the impact of 
cytokines on wasting in human subjects is difficult to study since they are rapidly 
internalized by cells.  Cytokines also act in an autocrine manner and their concentration in 
the blood is therefore not necessarily reflective of their influence on body systems.  
Conflicting results have been found when circulating cytokine concentrations were 
measured in AIDS patients.  Some studies found serum levels of the cytokine, tumour 
necrosis factor (TNF), to be elevated (Abad et al., 2002; von Sydow et al., 1994; Rautonen 
et al., 1991; Lahdevirta et al., 1988) while other studies failed to show high concentrations 
of TNF in the blood or any correlation between TNF concentrations and the magnitude of 
body mass loss in AIDS patients (Thea et al., 1996; Reddy et al., 1988).  The serum 
concentrations of another cytokine, interleukin-6 (IL-6), have been found to be raised in 
AIDS patients in various studies (von Sydow et al., 1991; Breen et al., 1990; van Snick el 
al., 1990).  Differing results may be related to disease stage and treatment differences 
between the study populations.  For example, those in the study by Thea et al. (1996) were 
not on ART, whilst Abad et al. (2002) have shown that wasting status could be related to 
cytokine concentrations. 
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Macallan and colleagues (1993) reported a close association between acute body mass loss 
episodes and opportunistic infections in males with stage 4 HIV infection.  It should be 
noted that periods of body mass gain and stability were also shown in this longitudinal 
study that lasted between 1.2 months and 3 years.  The median duration of body mass-
stable episodes was 10 months while the median duration of body mass-gain was 3 months.  
Recovery of body mass may be incomplete or interrupted by a new acute body mass loss 
episode.  Body mass gain did not necessarily lead to an improved prognosis as one of the 
individuals gained body mass virtually until death.  Gained body mass may not be optimal 
as a patient may be gaining fat or fluid instead of lean body mass. 
 
Different patterns of body mass loss are apparent from the study conducted by Macallan 
and colleagues (1993).  Some patients experienced acute body mass loss events followed by 
periods of body mass gain, while others showed a chronic, relentless pattern of body mass 
loss.  Nongastrointestinal infections were particularly associated with acute body mass loss 
events, while gastrointestinal disease (especially diarrhoeal diseases) was associated with 
chronic body mass loss.  The authors suggested that the metabolic disturbance related to 
chronic body mass loss is similar to a malnutrition response (despite reduced metabolic 
rate), while acute body mass loss resembles the disturbances seen in catabolic states with 
increased metabolic rate.  They also suggested that these different mechanisms can affect 
body composition, because of the tissue targeted during the wasting periods.  It is therefore 
also important to record the rate of body mass loss as well as episodes of body mass gain or 
stability.  This information can provide a better understanding of the type of body mass loss 
the individual is experiencing and how this body mass loss may be affecting body 
composition. 
 
Roubenoff et al. (1997) proposed the use of three distinct terms that describe body 
composition changes to distinguish between the different underlying processes.  They 
defined sarcopenia as the involuntary loss of skeletal muscle mass and reduced function, 
which may occur for various reasons including loss of alpha motor neurons in the spinal 
column, loss of endogenous growth hormone production, inadequate protein intake, 
dysregulation of catabolic cytokines (especially IL-6), loss of estrogen and androgen 
production and reduced physical activity.  The term cachexia describes an involuntary loss 
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of body cell mass or fat free mass, without a large decrease in BW.  This process might be 
due to an increased cytokine production which results in hypermetabolism.  Roubenoff et 
al. (1997) defined wasting as characterized by a parallel decline in body mass and BCM.  
Therefore, wasting is always accompanied by cachexia, but cachexia does not necessarily 
lead to wasting.  The authors suggested that an inadequate energy intake is necessary for 
the state of cachexia to develop into wasting, a process that is distinctive of advanced HIV-
infection.  It is therefore also possible for patients to maintain their body mass by adequate 
nutritional intake whilst experiencing a decrease in BCM, indicating the presence of 
cachexia but not wasting according to these definitions of Roubenoff et al. (1997).   
 
b. Interventions to reduce wasting 
 
Although many different factors may interact to cause wasting, nutritional status is clearly 
an important factor in progression of HIV-related wasting. After a review of the literature, 
Timbo and Tollefson (1994) concluded that the efficacy of nutritional supplementation 
should be investigated.  McKinley et al. (1994) showed that nutrition intervention (dietary 
assessment, intake analysis, counseling and provision of supplements) by dieticians can 
improve nutritional status. 
 
Berneis et al. (2000) demonstrated that oral nutritional supplementation combined with 
dietary counseling can diminish whole body protein catabolism and increase lean body 
mass in HIV infected subjects with modest to moderate malnutrition.  Although positive 
effects of whey protein supplementation on body mass were found by Agin et al. (1999), 
these researchers also showed that the combination of supplementation and resistance 
exercise can lead to gains in body cell mass and fat free mass, whereas supplementation 
alone leads to increases of fat mass. 
 
Resistance training has been shown to be an effective treatment to increase lean body mass, 
strength and functional status (Roubenoff & Wilson, 2001). Exercise may also have a 
positive effect on fat distribution, as shown by preliminary results of reduced trunk fat mass 
after 16 weeks of progressive resistance training with an aerobic component (Roubenoff et 
al., 1999a).  Roubenoff et al. (1999b) reported a lasting effect of increased lean body mass 
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up to 8 weeks after a resistance training programme was discontinued and normal activity 
was resumed.  These results show that resistance exercise may be a feasible option for 
maintaining lean body mass.  How this might be implemented in Sub-Saharan Africa 
remains to be investigated.  Exercise physiologists could play an important role in this 
regard by monitoring patients’ muscle function and assisting in educational programmes 
and exercise training sessions. 
 
Androgen administration has been found to increase lean body mass and quality of life 
parameters (Gold et al., 1996; Grinspoon et al., 1998), but these studies did not take into 
account the possible influence of exercise during the study period.  Therefore, it is not clear 
whether gains were from androgen administration alone, or also from exercise. 
Subsequently, the effect of testosterone administration in combination with resistance 
exercise was investigated (Grinspoon et al., 2000) and the increases in skeletal muscle fibre 
size that were found were similar to those of the previous, less controlled study, suggesting 
a synergistic role of exercise.  However, Bhasin et al. (2000) found that testosterone and 
exercise together did not produce greater gains than either intervention alone, suggesting 
that pharmaceutical intervention with anabolic agents is not a necessity for improved body 
composition even for HIV-infected men with low testosterone levels (less than 12.1 
nmol/L). From these data it was concluded that, taking into account the longer-term effects 
of androgen treatment on endocrine metabolism, exercise alone might be the ideal long-
term strategy to prevent or reverse muscle loss in HIV infected persons. 
 
Most anabolic agents still need to be researched extensively before being approved by the 
Food and Drug Administration of the United States (FDA) for use as treatment for HIV-
associated wasting.  Only growth hormone has been granted accelerated approval by the 
FDA, although the dosing recommendations still need to be determined.  A meta-analysis 
performed by Moyle et al. (2004) found that a dose of 6 mg recombinant human growth 
hormone per day had favourable effects on functional capacity and QoL.  Possible side-
effects from pharmacological doses of growth hormone include arthralgia, myalgia, 
diarrhoea and swelling and fluid retention in extremities.  Oxandrolone (5 – 20 mg/day) is 
approved by the FDA as a short-term treatment for body mass loss as a result of chronic 
infection, trauma, prolonged use of corticosteroids or surgery.  Nandrolone decanoate and 
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oxymetholone have been approved for the treatment of anaemia, but not wasting (Mulligan 
& Schambelan, 2002). 
 
Shevitz et al. (2005) compared the effectiveness of nutrition intervention alone (nutritional 
counseling and an oral liquid supplement) or nutrition intervention with oral androgen 
(oxandrolone) administration or nutrition intervention with progressive resistance training 
(PRT) for treating AWS.  Mid-thigh muscle cross-sectional area increased significantly in 
the oxandrolone and resistance training groups.  Self-reported physical functioning 
improved significantly only with PRT and this intervention improved quality of life more 
than the other two interventions. PRT was found to be the most cost-effective intervention 
while oxandrolone administration proved to be the least cost-effective intervention.  The 
calculation of the cost of PRT included the cost of nutrition intervention as well as 
gymnasium and personal training fees.  Input in terms of transportation and time by the 
participants was also taken into account.  This cost analysis may be inappropriate for Sub-
Saharan Africa, since gymnasiums and related infrastructures are not widely available in 
this area.  Researchers in South Africa should therefore explore other options of resistance 
training and investigate the cost and feasibility of implementing national exercise 
programmes or educational seminars for patients. 
 
Although there are many treatment options for HIV associated wasting, it is important to be 
able to distinguish between the types of body mass loss (losing lean body mass versus fat 
mass) and the relevant underlying mechanisms, before effective treatment can be 
considered.  Opportunistic infections, factors that limit food intake (relating to upper 
gastrointestinal tract pathology) and even psychiatric disorders need to be identified and 
addressed for exercise or nutritional support and supplementation to be successful 
(Williams et al., 1999). Effective monitoring of body mass loss and body composition 
changes, considered together with clinical and laboratory evidence, provide information 
about important processes (like hypermetabolism or proteolysis) occurring in the body.  
Clinical markers proposed include the cytokines discussed before and creatinine and urea 
nitrogen (American Dietetic Association and Dietitians of Canada, 2004) to indicate 
proteolysis. 
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3.1.2 The lipodystrophy syndrome 
 
During the late 1990s changes in the distribution of body fat became noticeable in patients 
taking HAART.  Initially protease inhibitors (PIs) were implicated as the offending agent 
(Brinkman et al., 1999), but similar lipid abnormalities have been shown in PI-naïve 
patients using two nucleoside reverse transcriptase inhibitors (NRTIs) (Galli et al., 2002). 
 
It has been hypothesized that PIs induce apoptosis of peripheral adipocytes by interfering 
with the cis-9-retinoic acid mediated stimulation of the retinoic X receptor which is 
involved in adipocyte differentiation (Carr et al., 1998).  Other possible avenues of 
metabolic disruption by PIs are the inhibition of lipoprotein receptor-related protein 
(involved in hepatic and endothelial clearance of chylomicrons and triglycerides) (Carr et 
al., 1998),  the suppression of the breakdown of nuclear sterol regulatory element binding 
proteins (nSREBP) in the liver and adipose tissue (potentially resulting in increased fatty 
acid and cholesterol biosynthesis in the liver, lipodystrophy and insulin resistance), 
suppression of proteasome mediated breakdown of nascent apolipoprotein B in the liver 
and the suppression of GLUT-4 expression in muscle and adipocytes (Hui, 2003). 
 
NRTI’s have been shown to inhibit DNA polymerase γ (responsible for mtDNA 
replication) (Lewis & Dalakas, 1995; Brinkman et al., 1998).  Brinkman et al., (1999) have 
hypothesised that NRTI’s cause mitochondrial toxicity. They proposed that this toxicity is 
the predominant cause of HAART-related lipodystrophy and that protease inhibitors then 
aggravate the condition.  Currently lipodystrophy is “considered to be an adverse effect of 
antiretroviral therapy, not limited to a specific drug or class of drugs” (Malinkovic & 
Martinez, 2005). 
 
The greatest obstacle for consensus on the aetiology of the lipodystrophy syndrome is 
probably the lack of a universally accepted definition.  Defining the syndrome proved to be 
more difficult than initially supposed.  To this date, there still is no practical definition for 
lipodystrophy (Milinkovic & Martinez, 2005).  For a patient it simply involves the loss of 
fat in the face and arms, which may or may not be accompanied by an expanding waistline 
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or even the development of a “buffalo hump” (increased fat deposition in the dorsocervical 
area).  These changes have profound social and clinical implications.  It may force a person 
to disclose his or her status to enquiring friends and it may influence adherence to the drug 
regimen.  The syndrome is also associated with metabolic abnormalities like dyslipidaemia, 
glucose intolerance, diabetes, hyperinsulinemia and insulin resistance (Salomon et al., 
2002; Brinkman et al., 1999; Carr et al., 1998).  These features resemble the characteristics 
associated with the metabolic syndrome X. 
 
Metabolic syndrome X has been described and studied since 1988, mainly in patients 
without HIV.  It is a condition that frequently arises from a lifestyle that favours a high fat 
intake, chronic psychological stressors and low physical activity.  Components of the 
syndrome include visceral and generalized obesity, fatty liver, hypertension, endothelial 
dysfunction, renal dysfunction, polycystic ovary syndrome, inflammation, 
hypercoagulability and atherosclerosis (Miranda et al., 2005; Mehta & Reilly, 2004). 
 
Although controversial, there are a few accepted definitions for this metabolic syndrome.  
These definitions commonly include the co-existence of conditions like glucose 
intolerance, central obesity, dyslipidaemia and hypertension.  A body mass index (BMI) 
greater than 30, a waist circumference more than 102 cm for men or 89 cm for women or a 
waist-to-hip ratio more than 0. 90 for men and 0.85 for women are some of the physical 
criteria that are considered to indicate the presence of metabolic syndrome X (Miranda, et 
al. 2005). 
 
Such clear and practical definitions or criteria do not yet exist for the lipodystrophy 
syndrome.  Instead, the subjective description of body fat changes based on reports from 
patients in combination with clinical evaluation are still used extensively to define 
lipodystrophy (Milinkovic & Martinez, 2005).  A list of clinical aspects and observable 
characteristics has been compiled (see Table 3), but objective criteria still need to be 
formulated (Salomon et al., 2002; Brinkman et al., 1999). 
 
The Lipodystrophy Case Definition Study generated a definition of lipodystrophy but it is 
too complex to use in clinical practice and therefore it does not qualify as a practical 
Stellenbosch University http://scholar.sun.ac.za
 35
definition of lipodystrophy (HIV Lipodystrophy Case Definition Study Group, 2003).  This 
definition relies on parameters gathered from laboratory testing, anthropometry and 
radiology (computed tomography scanning and dual X-ray absorptiometry).  Availability of 
equipment and the cost involved in obtaining the required parameters limit the application 
of this definition. 
 
Table 3:  Clinical aspects of the lipodystrophy syndrome (Salomon et al,. 2002; Rodwell 
et al., 2000, Carr et al., 1999). 
Fat accumulation 
 Abdominal obesity 
 Dorsocervical pad (“Buffalo hump”) 
 Cervical hypertrophy 
 Lipomas 
 Adipomasty 
Fat loss 
 Face wasting (reduction or absence of subcutaneous tissue on the cheeks with sparing of 
the facial musculature) 
 Loss of subcutaneous fat of extremities 
 Loss of gluteal mass 
Biological abnormalities 
 Glucose intolerance, diabetes, hyperinsulinemia and increased insulin resistance 
 Hypertriglyceridemia 
 Hypercholesterolemia: increased LDL cholesterol; decreased HDL cholesterol 
 
Some patients show only regional fat loss (lipoatrophy, usually of peripheral regions or 
face) or regional fat gain (lipohypertrophy, usually intra-abdominal or dorsocervical) (Carr 
et al., 1999).  Therefore, one may question the classification of the observed body fat 
changes as a single “lipodystrophy syndrome”.  Is lipoatrophy a separate syndrome or a 
component of the lipodystrophy syndrome?  This uncertainty makes the monitoring and 
assessment of the condition even more difficult.  Carr et al. (1999) found that self-
assessment, physical examination, measuring fasting triglycerides and C-peptide as well as 
the measurement of central adiposity with dual X-ray absorptiometry (DXA) to be useful in 
the diagnosis of the syndrome.  Since DXA is an expensive and frequently unavailable 
technology in a typical rural clinic, I suggest that self-assessment and physical examination 
(which are subjective) should be combined with objective anthropometry measurements to 
assess and monitor lipodystrophy in South African clinics.  Nurses and exercise 
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physiologists who have been trained in the methods of anthropometry, could perform these 
assessments. 
 
3.3. Monitoring body composition changes 
 
The human body can be considered to be composed of various structural and functional 
compartments.  There are cellular and non-cellular compartments, aqueous and non-
aqueous compartments, as well as fat and non-fat compartments (Brooks et al., 2001).   
 
Whole body:  Body mass (BW) can be divided into fat mass (FM) and fat free mass (FFM).  
Fat free mass includes the skeleton, water, muscle, connective tissue, organ tissues and 
teeth.  FM can be divided into essential and non-essential fat.  Essential fat is composed of 
the lipids that are incorporated into organs and tissues (cellular membranes, nervous tissue, 
mammary glands, heart, lungs, liver, etc.).  Non-essential fat is excess fat stored in adipose 
tissue (Brooks et al., 2001). 
 
The metabolically active cellular component of FFM is referred to as the body cell mass 
(BCM).  The extracellular component of fat free mass (ECM) contains solids (bone, fascia 
and cartilage) and fluids (plasma, lymph and interstitial fluid) (Wang et al., 1992).   
 
Fat free mass can be calculated by subtracting the FM from the BW.  An indirect laboratory 
method of measuring body composition is hydrostatic weighing.  This method is often seen 
as a “gold standard” and it has been used to develop equations so that body composition 
can be calculated from skinfold measurements (Brooks et al., 2001). 
 
Lean body mass (LBM) can be calculated by subtracting FM (as calculated from 
hydrostatic weighing) from body mass.  Therefore, LBM and FFM are essentially the same 
body compartment but sometimes a small distinction is made between the two concepts.  
Bioelectric impedance analysis (BIA) is a technique that measures the conductivity of the 
body.  When LBM is measured by bioelectrical impedance analysis, LBM corresponds with 
BCM, extracellular water (ECW) and intracellular water (ICW).  This is because the 
aqueous compartments and lean tissue conduct electricity more rapidly than fat and BIA 
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measures how easily electricity flows through the body.  Lean body mass then represents 
tissue that is highly conductive.  When subtracting FM from BW, the result is usually 
referred to as FFM (Brooks et al., 2001; Melchior et al., 1999). 
 
These are the most important categories and their relationships to each other: 
BW  = FM + FFM   
FFM  = BCM + ECM 
BW  = FM +BCM + ECM  
LBM  = BCM + ECW + ICW 
 
Laboratory methods of measuring body composition include dual X-ray absorptiometry 
(DXA), densitometry (also known as underwater or hydrostatic weighing), magnetic 
resonance imaging (MRI), neutron activation analysis and biochemical techniques (total 
body potassium (TBK) analysis, total body water (TBW) and inert gas absorption).  Field 
test methods are usually validated against standard laboratory methods (hydrostatic 
weighing, TBK and DXA are considered gold standards).  Anthropometry and skinfold 
measurements (SKF), ultrasound and BIA are considered to be field tests (Brooks et al., 
2001). 
 
Bioelectric impedance analysis has been used extensively to measure body composition in 
HIV-infected populations (Wilson et al., 2002; Forrester et al., 2002; Swanson et al., 2000; 
Kotler et al.,1999; Bell et al.,1997).  Although this method is considered to be an 
acceptable alternative to DXA or TBK when resources are limited, it has been shown to 
produce highly variable estimations of FM and FFM in comparison to DXA and TBK 
among HIV-infected men and women with AIDS wasting (Corcoran et al., 2000).   
Additionally, Corcoran and colleagues (2000) showed that FFM assessed by DXA was 
most highly correlated with TBK in men and women while BIA and skinfold thickness 
analysis were less well correlated with TBK.  They showed a significant difference in the 
determination of FFM by BIA (using the standard RJL Systems Inc software) compared to 
DXA resulting in an overestimation of FFM by 1.5 ± 2.9 kg for men (p < 0.001) and 2.0 ± 
2.6 kg for women (p < 0.0001).  When compared to DXA, skinfold thickness analysis 
resulted in differences in FFM estimations that were on average less significant (1.2 ± 3.4 
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kg overestimation for women (p = 0.01) and 1.0 ± 3.0 kg underestimation for men (p = 
0.02)) than those differences described above between BIA and DXA.   
 
Estimating FM from skinfold thickness analysis resulted in an overestimation of 1.3 ± 3.0 
kg in men and an underestimation of 1.0 ± 3.3 kg for women compared to DXA (Corcoran 
et al., 2000), whereas BIA (with the RJL equation) underestimated the FM of men with 1.1 
± 2.8 kg and 1.8 ± 2.5 kg for women.  Different equations used with BIA resulted in highly 
variable estimations of FFM and FM (overestimations of up to 6.2 ± 4.1 kg and 
underestimations of up to 5.9 ± 4.2 kg were shown).  Body fatness also influenced the 
prediction of FFM by BIA in comparison to DXA.  FFM was overestimated more in 
patients with greater body fat. 
 
The above publication is especially relevant because all the participants were HIV-infected 
and showed signs of AIDS wasting (body mass < 90% of ideal body mass and/or body 
mass loss > 10% of original).  The study clearly demonstrates that the results obtained from 
BIA measurements are highly variable and dependant upon the equation used. A 
disturbance in body water compartments (manifesting as a relative increase in extracellular 
water volume) has been linked to HIV-infection and AIDS wasting (possibly related to 
protein-calorie malnutrition (PCM)) (Paton et al., 1998; Bell et al., 1997). Such 
disturbances can influence determinations made by using TBK and BIA (Wang, et al, 
1992).   
 
Selecting an appropriate method of measuring body composition is therefore a difficult 
task.  In a resource-poor setting using TBK and DXA is virtually impossible, because of 
cost, space, additional facilities and the expertise needed to operate the equipment.  
Although BIA is easy to perform, the apparatus is expensive.  Skinfold thickness analysis 
may be the ideal solution to assist in body composition measurements in resource-poor 
settings and rural clinics in South Africa because the equipment is much less expensive and 
the method is relatively easy to perform.  However, the reliability coefficients (R) of 
skinfold measurements have been shown to be relatively large when different technicians 
performed the same measurements on the same subjects with less error when the same 
technician repeated the measurements on the same subjects (inter-observer variability (R) = 
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0.858-0.999; intra-observer variability (R): 0.979-0.999). Subsequent estimations of body 
composition exhibited comparatively higher reliability (inter-observer variability (R): 
0.975-0.999; intra-observer variability (R): 0.995-0.999) (Klipstein-Grobusch et al., 1997).  
Also, as illustrated in the Corcoran study (2000), skinfold thickness analysis can result in an 
over- or underestimation of FFM and FM in comparison to DXA, and although significant, 
these differences are usually less than one and a half kilogram.  This difference will also be 
less important if the changes in FFM and FM are monitored over time instead of merely 
focussing on the absolute values of these variables.  Therefore, it will have to be kept in 
mind that the same technician should perform all measurements on the same subject and 
that changes in the region of 1 kg are within measurement error for FFM. 
 
Regional:  Although skinfold thickness analysis can provide useful estimations of changes 
in FFM and FM they can also provide more detailed information on regional changes in fat 
distribution.  The skinfold thickness values that were used in the above mentioned study 
were from the subscapular, biceps, triceps and supra-iliac sites and were consequently used 
to determine percentage of body fat by the equations of Durnin and Womersley (1974). 
 
It is sometimes also useful to distinguish between subcutaneous fat (SCF) and intra-
abdominal fat (IAF).  Subcutaneous fat then represents non-essential fat in adipose tissue 
and IAF is the protective fat that surrounds the intestinal organs and therefore, if not 
excessive, it is a type of essential fat. 
 
The technique of obtaining skinfold thickness measurements has to be learned and 
practised, but it requires some technical knowledge of standardized procedures (NHANES 
III, 1988).  Nurses could be trained to perform this method relatively easily (as an 
additional skill to their existing clinical expertise) and it may assist greatly in the 
monitoring and diagnosis of patients.  The measurement of circumferences at specific sites 
is another anthropometry method that is also simple to perform (provided the specific 
landmarks are understood) and could also be helpful with body composition assessments.  
Anthropometric measurements have the advantage that changes at specific sites can be 
monitored, which is especially of concern with iatrogenic lipodystrophy.  Increases in waist 
girth and decreases in leg and arm circumferences could be valuable indicators when 
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lipodystrophy is suspected in patients.  Exercise physiologists that are specifically trained 
to obtain skinfold thickness measurements and anthropometric circumferences can also 
make an important contribution in a clinical setting, especially with regard to lifestyle 
recommendations that may result from this information. 
 
3.4 Quality of life 
 
The number and severity of HIV-related symptoms has been shown to be associated with a 
person’s perceived quality of life (QoL) (Cleary et al., 1993).  The improvement in 
treatment options for HIV/AIDS has led to an increased interest in and assessment of QoL 
of infected individuals (Gielen et al., 2001; Wu, et al. 1997). 
 
The concept of QoL includes multiple aspects of life satisfaction (like sense of security, 
control over one’s environment and spiritual fulfilment) that relate to physical functioning, 
mental health status and social role functioning (Gielen et al., 2001).  Questionnaires 
usually include various “dimensions” or aspects of QoL like global health perceptions, 
psychological functioning, self-care, mobility etc. (Burström et al., 2001; Lenderking et al., 
1997). 
 
The MOS-HIV questionnaire (HIV specific scales adapted from the Medical Outcomes 
Survey) is one of the most widely used questionnaires for the measurement of QoL, 
especially in the USA (Lenderking et al., 1997; Wu et al., 1997).  Different versions of the 
questionnaire exist, varying in length, content and language.  The different forms have been 
validated and shown to be reliable in various cities of the USA as well as London (Chan & 
Revicki, 1998; Wu et al., 1997; Lenderking et al., 1997; Carretero et al., 1996). 
 
Although the MOS-HIV has been used in South Africa (Wu et al., 1997), there seems to be 
no available data describing its validation in a South African population.  A European 
questionnaire (EQ-5D) has been translated (into Xhosa) and validated in a South African 
population (Jelsma, 2003).  The original EQ-5D has been used extensively in various 
international studies including Japan, Canada and Zimbabwe (Burström et al., 2001; 
Jelsma, 2003). 
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The assessment of QoL by health workers can assist in the monitoring of patients with 
regard to the impact of treatment (Chan & Revicki, 1998; Wu et al., 1997).  A QoL 
questionnaire can also be a powerful research tool since it is usually easy to administer and 
inexpensive.  It can also expose unexpected findings, which may improve our 
understanding of effective treatment of patients.  For example, the study conducted by 
Gielen et al., (2001) showed a relationship between practicing more health promoting 
behaviours and improved mental health, physical functioning and overall quality of life.  
The participants of this study were all women (94% of which were African-American) and 
54.5% of the study group did not have a high school diploma.  A great number of these 
participants experienced sexual abuse and/or physical and/or sexual assault at some point in 
their lives.  The researchers concluded that relatively straightforward lifestyle changes (like 
eating well, exercising and getting adequate sleep) can make a difference even in a 
complicated context involving HIV disease, poverty and oppression. 
 
Resistance training and cycling has been shown to increase physical functioning and QoL 
in HIV-infected men and women (Agin et al., 2001; Roubenoff & Wilson, 2001; Stringer et 
al., 1998).  Cardiovascular exercise and strength training have been suggested as possible 
treatment interventions for conditions like the AIDS wasting syndrome (AWS) and the 
metabolic abnormalities associated with antiretroviral therapy (Scevola et al., 2003; 
Yarasheski & Roubenoff, 2001; Mars, 2000; Roubenoff et al., 1999a).  QoL, physical 
functioning and the HIV disease are therefore complexly interrelated and any study that 
investigates the impact of HIV disease on health or the treatment outcomes ART, should 
also include measurements of QoL.   
 
Therefore, this study has included the measurement of QoL with an easy-to-use version of 
the EQ-5D questionnaire (as validated by Jelsma, 2003) in addition to the anthropometric 
measurements of body composition changes that may indicate AWS or lipodystrophy. 
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4. Methods 
 
4.1 Ethical concerns 
 
The protocol was evaluated and approved by the Ethics Committee of the University of 
Stellenbosch (Sub-committee C, Tygerberg campus).  All relevant agencies and parties 
were contacted and consulted before the initiation of any measurements (including 
provincial and local administrators and government officials).   
 
Participants were recruited with the assistance of support group leaders and medical staff 
who informed possible candidates about the project and consequently referred them to the 
investigator.  Prejudice was still severe in the community that was investigated and the 
utmost discretion and confidentiality was observed at all times.  HIV-related stigma meant 
that individuals could not disclose their status to many people and family members were 
often oblivious to their condition.  It was therefore difficult to recruit a control group.  
Initially we attempted to recruit friends and family of our participants to serve as HIV-
negative participants, but this was clearly not possible in the communities in our region.  
Alternative ethically acceptable strategies of recruiting appropriate controls were outside of 
the scope of the present study. 
 
Before being accepted into the antiretroviral treatment (ART) programme, participants 
underwent thorough evaluation and counselling.  Each patient needed to demonstrate that 
she had at least one family member or close friend that could assist the patient during times 
of disability and with the taking of medication.  This “buddy” unfortunately also didn’t 
qualify as an appropriate control candidate since they were usually a poor match (being a 
husband or much older or younger). 
 
Appendix C contains the information sheets and consent forms that were used.  These 
forms were available in English and Afrikaans.  An interpreter was used on the day of 
recruitment to explain the protocol in Xhosa in cases where the participant could not 
understand English or Afrikaans adequately.   
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4.2 Participants 
 
Participants were recruited from clinics in the Stellenbosch area at the end of 2003 with the 
help of health workers involved with HIV-counselling and support groups.  In 2004, 
government-initiated programmes providing ART to selected HIV-infected patients were 
implemented at selected clinics.  We recruited additional participants from one of these 
clinics situated in the semi-rural community of Paarl.   
 
Therefore, some participants were enrolled into the study before ART was widely available, 
while other participants were enrolled while being assessed for qualification to enter a 
treatment programme. 
 
Only South African non-Caucasian women were recruited to participate in the study.  The 
only exclusion criterion was being pregnant, since it would influence body composition 
changes over time. 
 
4.3 Rural and clinical setting 
 
Since there was no space to meet and assess participants at the Stellenbosch clinics, 
measurements of this group were performed at the University of Stellenbosch.  Although 
the clinic at Paarl also had limited space, measurements were done at the clinic.  Open 
offices were used as they became available, since all consultation rooms were shared 
between counsellors, doctors, nurses and a dietician.  
 
Participants were reimbursed for travel expenses when they travelled for an appointment 
relating to the study.  Some of the measurements at Paarl were performed concurrently with 
dates that the participants had to see a doctor or collect medicine. 
 
The aim was to get at least one measurement every month for the first three months, a six-
month follow-up measurement as well as a one-year follow-up measurement for every 
participant.  Various participants missed several follow-up visits, whereafter new dates 
were scheduled.  Thus, the participants’ measurement dates do not follow a uniform 
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pattern, and for the purposes of data analysis their measurements were therefore divided 
into three main categories (baseline, short-term and long-term), which relate to the day of 
treatment initiation (TI) or the day of recruitment (R) into the study.  These temporal 
categories are indicated in Table 4. 
 
Table 4:  Categories for time periods for which data are available. 
ART group 
Time Point Description Weeks since TI (mean ± SD) 
Baseline Within one month before the initiation of treatment -4 to 0 weeks (-1 ±1) 
Short-term Within the first three months of TI 2 to 12 weeks (5 ±3) 
Long-term Within one and a half years of TI 42 to 65 weeks (52 ±7) 
TN group 
Time Point Description Weeks since R (mean ± SD) 
Baseline On the day of recruitment 0 weeks (0 ±0) 
Short-term Within the first three months after the day of recruitment 2 to 12 weeks (7 ±3) 
Abbreviations:  ART (antiretroviral treatment), TN (treatment naïve), TI (treatment initiation), R (day of 
recruitment). 
 
4.4 Data collection methods 
 
Detailed measurements of body composition were performed, whereas selected 
measurements were made for haematological parameters and quality of life (QoL). 
 
Body composition:  Participants removed all but their underclothes for all the 
anthropometric measurements except when height was determined, for which only shoes 
were removed.  Body mass was determined on a scale accurate to the nearest 100 g (Tanita, 
Tokyo, Japan).  A stadiometer was used to measure height and a Harpenden calliper (Baty 
British Indicators) for skinfold measurements.  Measurements included nine skinfold 
measurements (at the biceps, triceps, sub-scapular, mid-axillary, iliac crest, supra-spinal, 
mid thigh, calf and abdominal landmarks) and five circumferences (mid-arm, waist, hip, 
thigh and calf circumferences), all made using standard techniques (NHANES III, 1988).  
The landmark sites were marked for each measurement on every occasion.  All 
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measurements were made according to the guidelines specified by NHANES III, except for 
the waist circumference, which was taken midway between the lowest rib and the upper rim 
of the iliac crest.        
 
Haematology:  A registered nurse collected 5 ml blood from the cubital vein into EDTA-
vacutainer tubes (BD systems, Plymouth, UK).  The blood samples that were drawn in 
Stellenbosch were sent to a commercial pathology laboratory (PathCare) to determine CD4+ 
cell count using the AffordCD4 method.  Blood samples drawn at the Paarl clinic were sent 
to a national pathology laboratory at a government hospital (Tygerberg NHLS) for analysis.  
The CD4+ cell counts for any given patient were always done at the same laboratory and 
the coefficient of variation between the two laboratories is less than 5 %.   
 
The doctor consulting the patient at that time determined which blood parameters needed to 
be investigated according to the information needed for diagnosis and treatment. CD4+ cell 
counts and total white cell counts were usually done at least once every six months and 
viral load was determined after being on treatment for approximately a year, but not in any 
of the cases at baseline.  When enough clinical information was available for a particular 
patient, it was not always deemed necessary by the clinician to reassess the CD4+ count 
before the initiation of treatment.  Therefore, there are long intervals between the time of 
blood assessments and the actual anthropometry measurements for some of the participants. 
 
Quality of life:  A translated (original in English) and adapted QoL assessment tool (EQ-
5D, hereafter called questionnaire) was used for three reasons.  Firstly it is simpler than the 
MOS-HIV questionnaire (Wu et al., 1997); secondly it was previously translated into 
appropriate languages for this study region (Jelsma, 2003) and thirdly there were only three 
rating levels (Burström et al., 2001).  The questionnaire was available in Xhosa, English 
and Afrikaans.  The questionnaire had been developed and validated in all three languages 
at UCT Medical School according to accepted methods (Jelsma, 2003).  For this study, 
pictures were added to the questionnaire to make it simpler and easier to explain to 
participants.  The original, as well as the changed version, are included in Appendix C.  The 
questionnaire requires the respondent to rate her perception of mobility, self-care, usual 
activities, pain or discomfort and depression or anxiety according to three levels of 
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experience (having no problems, some problems or a lot of problems).  The participant was 
also required to specify an overall score out of a hundred, indicating what her state of health 
felt like on that day.   
 
Community counsellors with basic counselling training, who regularly worked at the clinic, 
acted as interpreters.  An interpreter assisted with the QoL questionnaire when it proved 
necessary. 
 
4.5 Data analysis 
 
Anthropometry calculations: The equations provided by Frisancho (1981) were used to 
calculate the upper arm muscle (UAMA) and fat (UAFA) areas for the participants.  These 
equations are given below for measurements in mm: 
 UAMA  = [{upper arm circumference – (π x triceps skinfold)}2] / 4π 
 UAFA  = [π/4 x (upper arm circumference/ π)2] – UAMA 
 
Tables from the same publication were used to determine within which percentile 
categories these calculated parameters as well as the values for triceps skinfold and arm 
circumferences fell.  These tables were also used to convert each participant’s arm 
circumference to a percentage of ideal arm circumference (%IAC), using the value at the 
50th percentile as reference value.  
 
The equations of Durnin and Womersley (1974) (DW) were used to estimate average body 
density (D, g/mL) from four skinfolds (biceps, triceps, sub-scapular and supra-illiac).  Body 
density was also estimated with an equation of Pollock et al. (1975) (Pol) using three 
skinfolds (triceps, thigh and supra-illiac) as well as the hip circumference.  Both sets of 
equations were specifically developed for women and are given below: 
 
The equations of Durnin and Womersley (1974): 
D (DW) = C – [M x Log10 x ∑four skinfolds] 
Where C  = 1.1599 (20 to 29 years) or 1.1423 (30 to 39 years) or 1.1333 (40 to 49 
years) or 1.1339 (50 and older)  
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and M  = 0.0717 (20 to 29 years) or 0.0632 (30 to 39 years) or 0.0612 (40 to 49 
years) or 0.0645 (50 and older). 
 
The equation of Pollock et al. (1975) (Pol): 
D (Pol) = 1.1470292 – [0.0009376 x ∑three skinfolds] + [0.000003 x (∑three 
skinfolds)2] – [0.0001156 x age in years] – [0.0005839 x hip 
circumference in cm] 
 
Fat mass (FM) and fat free mass (FFM) were then calculated from the body density using 
the Siri (1956) equation: 
 FM (kg)  = Body mass (kg) x [(4.95/D) – 4.5] 
 FFM (kg)  = Body mass (kg) – Fat mass (kg) 
 
Additionally, each participant’s body mass was expressed as a percent of ideal body weight 
(IBW) using the following formula (Baylor College of Medicine, 2003): 
 %IBW  = Body mass (kg)/Ideal body mass (kg) x 100 
 IBW  = 45.5 kg + 0.9 kg/cm if height is over 152 cm 
 
Table 5 summarizes the anthropometric variables that are related to wasting and nutritional 
status, or lipodystrophy.  The only variable in traditional anthropometry that is in part 
related to lipodystrophy is the waist to hip ratio.  However, this variable does not account 
for fat distribution in sub-cutaneous vs. intra-abdominal sites.  Therefore, I attempted to 
estimate the intra-abdominal circumference (the waist circumference without the layer of 
subcutaneous fat) by applying the same reasoning as when arm muscle circumference and 
area is estimated from arm circumference and triceps skinfold. 
 
This approximation was based on the following assumptions: the trunk at the level of the 
waist is a circle, the abdominal skinfold measurement provides an estimation of 2x the 
thickness of the sub-cutaneous fat and that it is distributed similarly around the whole 
circle. This novel variable was termed the “intra-abdominal indicator” (IAI) and the 
following equation was used to calculate this variable: 
 IAI (cm)  = [(waist circumference (cm)/2π) – (abdominal skinfold (cm)/2)] x 2π  
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Table 5:  Variables that were considered to be indicators of wasting status or 
manifestations of lipodystrophy, or both. 
Variables that relate to 
wasting and nutritional status lipodystrophy 
Body mass (BM) Waist to hip ratio (W:H) 
Percent of ideal body mass (%IBW) Intra-abdominal indicator (IAI) 
Percent of ideal arm circumference (%IAC) Intra-abdominal indicator to hip ratio (IAI:H) 
Upper arm fat area (UAFA) Upper arm fat area (UAFA) 
Upper arm muscle area (UAMA)  
Thigh skinfold  
Thigh circumference  
Fat mass index (FMI)  
Fat free mass index (FFMI)  
 
The ratio between the IAI and the hip circumference was calculated, which could be 
considered similar to the waist to hip ratio but excluding estimated sub-cutaneous 
abdominal fat.   
 
Statistical analysis: Prior to any group comparisons or assessments of change over time, 
descriptive statistics (mean ±SD) for the whole group are presented for variables related to 
disease status. Statistical analysis of the data was performed with the assistance of a 
professional statistician.  All statistical analyses were done with a computer software 
package (STATISTICA v.7, StatSoft, Inc., Tulsa, USA).  A p-value of less than 0.05 was 
considered to indicate statistical significance.  The analysis approach was designed to make 
three distinctly different comparisons: 
 
(i) In order to determine if the ART and TN groups differed prior to treatment with 
antiretroviral medication, the baseline values of variables that relate to those mentioned in 
Table 5 of ART (participants who subsequently went on antiretroviral medication) and TN 
(participants not on treatment during this study) were compared using a Mann-Whitney U 
test because data was not normally distributed. 
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(ii) Thereafter, all the variables of the ART group and the TN group for baseline and short-
term time points were compared using main effects ANOVA, to determine any main effect 
of time or group or both (interaction).  A Bonferroni post hoc analysis was applied when 
significant differences were detected.  Bootstrap means were calculated as deemed 
necessary by a statistician for one variable (frontal thigh), because of too many outliers.  
For some variables the change from baseline to short-term was also calculated prior to 
comparisons between the two groups.  In these cases the two group comparisons were done 
using a Mann-Whitney U test.  
 
(iii) Only for ART, changes over three time-points were also investigated in a separate 
analysis (repeated measures ANOVA, with Bonferroni post hoc test if applicable), to 
determine if differences existed between baseline, short-term and long-term time points. 
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5. Results 
 
5.1 Overview  
 
A total of 19 participants were recruited and participated in the study beyond the initial 
screening.  A unique subject number was given to each participant to facilitate 
administration and the organization of data as well as ensuring the anonymity of the 
participants.  For data analysis each subject was then assigned a group code, “EXCL” (the 
code given to participants who were excluded from the final analyses) or “TN” or “ART” 
respectively denoting groups belonging to the “treatment naïve” or “antiretroviral 
treatment” groups.  All recruited participants, their group codes and essential information 
are shown in Tables 6a and 6b. 
 
Table 6a:  Descriptive information of participants excluded from further data analysis 
(EXCL 1-5). 
Subject Age (years) Ethnicity Date of TI 
Baseline 
CD4+ 
(cells/μL)  
Interval 
(days) 
WHO 
stage 
Body 
mass 
(kg) 
%IBW 
(%) 
EXCL1 43.9 Mixed descent / Afrikaans speaking 14-May-04 5 N/A N/A 45.9 101 
EXCL2 34.5 Mixed descent / Afrikaans speaking none 116 N/A N/A 35.4 N/A 
EXCL3 33.6 Mixed descent / Afrikaans speaking 14-May-04 160 238 3 64.3 130 
EXCL4 34.3 Black / Xhosa speaking 28-May-04 86 28 N/A 68.2 N/A 
EXCL5 26.2 Black / Xhosa speaking unknown N/A N/A N/A 44.0 97 
Mean 34.5   92   51.6 109 
SD ±6.3   ±65   ±14.0 ±18 
Abbreviations: N/A – information not available; WHO – World Health Organization; TI – treatment 
initiation; %IBW – percent of ideal body mass.  Interval indicates the number of days between blood 
drawing and baseline measurements. 
 
One participant (EXCL2) passed away shortly after the first measurement, before receiving 
ART, due to lack of ability to overcome Tuberculosis (TB) despite treatment for this 
disease.  Two participants (EXCL1, EXCL3) had already been on treatment for two weeks 
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by the time the first measurements were completed and were therefore excluded from the 
groups that were used for statistical analysis.  One participant (EXCL4) declined further 
involvement in the study after the first measurements were done on the day of recruitment 
and was therefore also excluded from all except the data analyses in Tables 6a and 7.  
EXCL 5 could not be located for follow-up. 
 
Table 6b:  Descriptive information of participants belonging to the treatment naïve (TN 1-
6) and antiretroviral (ART 1-8) groups. 
Subject Age (years) Ethnicity Date of TI 
Baseline 
CD4+ 
(cells/μL)  
Interval 
(days) 
WHO 
stage 
Body 
mass 
(kg) 
%IBW 
(%) 
TN1 37.7 Black / Zulu speaking 15-Dec-03 65 32 N/A 60.8 134 
TN2 29.3 Black / Xhosa speaking unknown 235 92 N/A 57.0 98 
TN3 36.4 Black / Xhosa speaking 18-Mar-04 217 24 N/A 77.5 167 
TN4 34.2 Black / Xhosa speaking none 673 24 N/A 95.0 158 
TN5 36.0 Black / Xhosa speaking unknown 778 4 N/A 79.8 149 
TN6 29.9 Black / Xhosa speaking 8-Oct-04 190 115 4 57.3 114 
ART1 34.0 Mixed descent / Afrikaans speaking 7-May-04 139 87 3 75.8 153 
ART2 54.9 Black / Xhosa speaking 11-Jun-04 393 304 4 78.1 153 
ART3 35.1 Black / Xhosa speaking 9-Jul-04 110 105 2 58.9 107 
ART4 24.6 Black / Xhosa speaking 25-Jun-04 45 50 3-4 40.5 67 
ART5 40.9 Mixed descent / Afrikaans speaking 30-Jul-04 126 14 4 45.0 99 
ART6 22.7 Mixed descent / Afrikaans speaking 6-Aug-04 194 133 3 50.3 87 
ART7 33.9 Black / Xhosa speaking 13-Aug-04 192 73 3 41.7 92 
ART8 36.6 Black / Xhosa speaking 13-Aug-04 19 35 3 58.2 N/A 
Mean 34.7   241 78  62.6 121 
SD ±7.7   ±226 77  ±16.3 ±32 
Abbreviations:  Refer to the Table 6a.  Interval indicates the number of days between blood drawing and 
baseline measurements.  The mean and SD at the bottom of the table represent those values calculated for 
TN as well as ART participants.  
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Shortly after baseline measurements, one participant (TN1) relocated to her previous home 
in KwaZulu Natal where she received ART upon arrival.  Two other recruited participants 
(TN2, TN5) could not be contacted after two measurements and therefore it is assumed that 
they did not volunteer to have further measurements done.  Near the end of the protocol, 
one participant (TN3) started ART at the Tygerberg Hospital Infectious Diseases clinic.  
Another participant (TN4) showed a slow disease progression – maintaining a high CD4+ 
count and an absence of AIDS signs and symptoms.  She was not enrolled into a treatment 
programme for the duration of the study.  Finally, TN6 was enrolled for treatment.  She was 
not used as a subject in the ART group, because more complete data were available for her 
first two measurement sessions pre-ART.  Therefore, assessments that were done after she 
was enrolled into the treatment programme were excluded. 
 
Despite the fact that 5 participants did not remain in the study (EXCL 1 to 5), their data are 
included in Table 7 to indicate the typical characteristics of subjects willing to have the 
majority of measurements done at least once (see Table 7).  
 
Table 7:  Descriptive statistics of all participants for selected variables on the day of 
recruitment. 
 WCC (cells/nL) 
QoL 
(%) 
BMI 
(kg/m2) 
Waist : 
Hip ratio 
Triceps 
skinfold 
(mm) 
Biceps 
skinfold 
(mm) 
Body 
fat, DW 
(%) 
UAC 
(cm) 
Median* 4.7 70 22.7 0.79 13.8 7.2 24.5 25.9 
n 12 18 16 19 19 19 19 19 
Min 2.6 20 14.3 0.64 3.8 2.4 8.4 16.6 
Max 8.8 100 33.5 0.87 42.6 26.7 40.7 38.2 
Abbreviations: WCC – total white cell count; QoL – overall quality of life score; BMI – body mass 
index; DW – from the equations of Durnin and Womersley (1974); UAC –upper arm circumference.      
* Due to skewed distribution of the data, median rather than mean is reported.  
 
As mentioned in the Methods section, several appointments were missed or rescheduled for 
various participants.  Therefore, the pattern of follow-up measurements appears to be 
somewhat inconsistent.  Figure 3 is a graphic display of the time points at which 
measurements were done.  Since the baseline time-point (week 0) for the ART group 
represents the date of treatment initiation and the first measurements were done before 
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starting treatment for some participants, the time-point for their first measurement is 
sometimes indicated with a negative number of weeks. 
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Figure 3:  Time points for anthropometry measurements indicated as weeks since baseline 
measurement for TN and weeks since treatment initiation for ART.  Group codes: TN1 to 
6 represent the TN group, while ART1 to 8 represent the ART group and EXCL1 to 5 
were subjects who were excluded due to inadequate data (no follow-up or no true pre-
treatment baseline).   
 
Ultimately, 8 participants were included in the group designated as the “ART” group 
(ART1-8: antiretroviral treated participants) and 6 participants were included in the “TN” 
group (TN1-6: treatment naïve participants).  Baseline and short-term information was 
available for all subjects in the TN group.  All the participants included in the ART group 
had true baseline information (before the initiation of treatment) and follow-up information 
for the short-term as well as long-term time points (as specified in the Methods section).  
One participant of the ART group did not have anthropometry data for the long-term time 
point and another ART participant’s height was never determined.   
 
The rest of the Results section will be devoted to the findings of the statistical analyses 
relating to time and group comparisons.  Section 5.2 presents the baseline data of both 
groups.  Section 5.3 will present the results from ANOVA comparing the ART and the TN 
groups at baseline and short-term, while Section 5.4 will show the comparisons between 
baseline, short-term and long-term for the ART group. 
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5.2 Baseline 
 
The descriptive statistics of selected variables of the ART and the TN groups are shown in 
Tables 8 and 9.  Variables that relate to clinical aspects of the disease are shown in Table 8, 
while those variables that relate mainly to anthropometry are shown in Table 9. 
 
From Table 8 it may appear that body mass (BM) and body mass index (BMI) were 
different between the two groups, but there was only a trend (p = 0.09).  Percent of ideal 
body mass (%IBW) was also not significantly different (p = 0.12).   
 
Table 8:  Descriptive statistics of selected variables at baseline for the TN and ART 
groups.  These variables are important considerations during clinical evaluation.  
 TN ART 
Variable Mean ±SD n Mean ±SD n 
Body mass (kg) 71.2  ±15.4 6 56.1  ±14.6 8 
Body mass index (kg/m2) 28.2  ±5.3 6 22.4  ±6.4 7 
Percent of ideal body mass (%) 137  ±26 6 108  ±33 7 
CD4+ count (cells/μL) 384  ±319 5 118  ±67 7 
CDC immune category 2  ±1 5 3   ±0 * 7 
White cell count (cells/nL) 5.4  ±2.2 5 5.1  ±1.7 5 
Statistical analysis by Mann-Whitney U-test:  * p < 0.05.  Each participant’s CD4+ count was classified 
according to the CDC immune category where category 1 represents a CD4+ count of 500 or more, 
category 2 represents a CD4 category of 200 - 499 and category 3 represents a CD4+ count less than 200 
(see section 2 (disease background) for more information about these categories).  
 
The mean CD4+ counts were not different at baseline (p = 0.09), but the CDC immune 
category was significantly different between the two groups (p < 0.05).  The TN group 
exhibited large inter-individual variation for the baseline CD4+ cell counts and both groups 
had large inter-individual variation for overall QoL scores (Figure 4). However, the means 
for both CD4+ cell count and QoL scores were not significantly different between groups. 
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Figure 4:  CD4 and QoL information for ART and TN groups at baseline and short term 
or long-term time points. The box plots represent mean ± SE, while the whiskers 
indicate ± SD.  Outliers are represented by an open circle (  ). 
 
The only anthropometry variables that were significantly different at baseline were the arm 
circumference (AC), percent of ideal arm circumference (%IAC) and upper arm fat area 
(UAFA) all of which were higher in the TN group (p < 0.05) (Table 9).  A few of the other 
variables shown in Table 9 approached statistical significance (p-value between 0.05 and 
0.09).  The p-values for biceps and triceps skinfolds both equaled 0.05.  Waist 
circumference and upper arm muscle area (UAMA) also approached statistical significance 
with p-values of 0.07.  In all these, TN tended to be higher than ART. 
 
Fat free mass index as estimated by the Durnin and Womersley (1974) equation (FFMI, 
DW) was 18.9 kg/m2 ±1.7 for the TN group and 16.3 kg/m2 ±2.4 for the ART group.  The 
corresponding values for fat mass index (FMI, DW) were 9.3 kg/m2 ±4.1 and 6.0 kg/m2 
±4.0 for the TN and ART groups respectively.  Although none of the fat mass or fat free 
mass indices were significantly different between the two groups, the different equations 
for both FMI and FFMI resulted in dissimilar differences between the groups.  The p-values 
for FMI and FFMI as estimated by the Pollock et al. (1975) equation (Pol) which included 
one lower body measurement, were 0.17 and 0.12 respectively, while the FFMI estimated 
by the Durnin and Womersley (1974) equation (DW) using only upper body measurements, 
approached statistical significance (p = 0.06).  In summary, the upper body appeared to 
Stellenbosch University http://scholar.sun.ac.za
 56
show signs of wasting of both muscle and fat in ART despite the fact that means for BMI 
and %IBW were normal. 
 
Table 9:  Descriptive statistics of measured and calculated anthropometry variables of 
the TN and ART groups at baseline. 
  TN ART 
 Variable Mean ±SD n Mean ±SD n 
Arm circumference (cm) 32.1  ±5.3 6 24.7  ±5.3 * 8 
Biceps skinfold (mm) 16.6  ±9.6 6 7.1  ±5.0 † 8 
Triceps skinfold (mm) 27.3  ±14.6 6 13.9  ±8.8 † 8 
Thigh skinfold (mm) 38.4  ±8.4 5 36.9  ±13.9 8 
Thigh circumference (cm) 57.3  ±6.9 6 48.1  ±9.0 8 
Abdominal skinfold (mm) 22.6  ±12.0 6 15.7  ±9.9 8 
Waist circumference (cm) 81.3  ±11.8 6 72.0  ±7.8 † 8 
M
ea
su
re
d 
va
ri
ab
le
s 
Hip circumference (cm) 105.6  ±13.6 6 94.5  ±14.4 8 
Percent of ideal arm circumference (%) 113  ±18 6 87  ±17 * 8 
Upper arm fat area (mm2) 3954  ±2396 6 1699  ±1317 * 8 
Upper arm muscle area (mm2) 4455  ±821 6 3332  ±938 † 8 
Fat mass index, Pol (kg/m2) 8.7  ±3.9 5 6.0  ±4.2 7 
Fat free mass index, Pol (kg/m2) 18.5  ±2.4 5 16.4  ±2.8 7 
Waist to hip ratio 0.77  ±0.07 6 0.77  ±0.08 8 
Intra-abdominal indicator to hip ratio 0.71  ±0.08 6 0.72  ±0.08 8 C
al
cu
la
te
d 
va
ri
ab
le
s 
Intra-abdominal indicator (cm) 74.2  ±9.6 6 67.1  ±4.8 8 
Statistical analysis by Mann-Whitney U-test:  * p < 0.05;  † p < 0.09 
 
Five QoL dimensions were assessed.  Although overall score for QoL was used in this 
study as an indicator of general status along with clinical data, the individual dimensions 
are presented to indicate possible effects of wasting on factors such as mobility, self-care, 
etc. 
 
Figure 5 shows pie charts of the percentages of TN and ART participants who reported no 
problems, some problems or severe problems for each the five QoL dimensions at baseline.  
Because of low subject numbers, no statistical analysis was done on the QoL data, however 
it seems as though the TN participants generally reported having fewer problems than the 
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ART participants with mobility and usual activities. Only for anxiety/depression did any of 
the TN subjects report a severe problem.  
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Figure 5:  Pie charts representing the percentage of TN (n = 5) and ART (n = 8) subjects in 
each group who fitted into one of three categories for variables describing quality-of-life. 
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The results of the comparisons that were made between the groups at baseline and short-
term will be presented in the next section. 
 
5.3 TN and ART group comparisons over time   
 
The short-term time point was 7 ±3 weeks since the baseline measurement for the TN and 5 
±3 weeks since treatment initiation for ART.  The variables used to assess immune and 
disease status (CD4+ count, CDC category and WC count) were not done by the clinic on a 
frequent basis.  Quality of life assessments were also not done as frequently as the 
monitoring of body composition.  Individual QoL data for the TN group were available, but 
for the ART subjects only 2 repeated their QoL questionnaire at the short-term time-point.  
This was because their clinical assessments took much longer and the QoL interview 
required an interpreter, who was not available at follow-up.  However, since disease 
progression and treatment did not change for the TN subjects from baseline to short-term 
follow-up, I present these data as an indication of stability of the scores.  The TN group’s 
overall QoL score was 77% ±26 vs. 76% ±19 at baseline and short-term time points 
respectively. The Spearman rank order correlation coefficient for these 5 subjects was r = 
0.92. 
 
Figure 6 displays the body mass, BMI and %IBW for both groups at baseline and short-
term time points and indicates no group differences and no significant changes over time.   
Although, there was a tendency for a group difference in body mass (Panel A; p = 0.07), 
this tendency became clearly insignificant when corrections for height were made.  The p-
values for the difference in body mass index (BMI) and percent of ideal body mass 
(%IBW) were equal to 0.09 (Panel B) and 0.11 (Panel C) respectively.  Nutritional or 
wasting status is also frequently assessed by determining the upper arm circumference and 
determining whether or not this deviates from published normal values (% ideal upper arm 
circumference, see Panel D).   
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Figure 6:  Body mass, body mass index, percent of ideal body mass and percent of ideal 
arm circumference for ART and TN groups at baseline and short term time points.  * 
indicates statistical significance p < 0.05.  The box plots represent mean ± SE, while the 
whiskers indicate ± SD.  Outliers are represented by an open circle (  ). 
 
In both groups it was possible to do regular anthropometry measurements so that for most 
variables the data set is complete for both baseline and short-term follow-up.  The ART and 
TN groups were compared to determine if certain anthropometry variables were 
consistently different between the groups (main effect of group), changed similarly over 
time in both groups (main effect of time), or changed differently within the first three 
months of being on antiretroviral treatment compared to subjects who experienced little or 
no change in clinical status over a similar short time period (interaction between group and 
time). 
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In contrast to the results of the Mann-Whitney U test (which found that only the %IAC and 
UAFA were different between the groups at baseline, see section 5.2), findings from the 
main effects ANOVA revealed more differences between the groups.  As with the previous 
analysis the TN group had significantly higher %IAC (Figure 6, Panel D) and UAFA 
(Figure 7, Panel A) but there were also a main effects of group for UAMA (Figure 7, Panel 
B) and biceps and triceps skinfolds.  All of these variables had a tendency to be different 
between groups with the previous analysis.  For all these anthropometry variables TN had 
higher values than the ART group (Biceps: TN: baseline: 16.6 ±9.6 and short-term 15.1 
±8.7 vs. ART: baseline: 7.1 ±5.0 and short-term 7.1 ±4.6 mm; Triceps: TN: baseline: 27.3 
±14.6 and short-term 27.4 ±10.6 vs. ART: baseline: 13.9 ±8.8 and short-term 14.7 ±8.0 
mm).  
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Figure 7:  Upper arm muscle and fat areas at baseline and short term time points for ART 
and TN groups.  * indicate statistical significance p < 0.05.  The box plots represent 
mean ± SE, while the whiskers indicate ± SD.  Outliers are represented by an open circle 
(  ). 
 
Several whole body variables were calculated in order to estimate overall changes in body 
compartments, specifically fat free mass and fat mass.  Since these variables are influenced 
by height, they are presented here as indexes relative to height squared as was previously 
done by Maia et al. (2005).  No significant differences between the two groups were 
evident, although there was a tendency for FFMI to be lower in ART than TN (DW only, 
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Panel A, p = 0.05).  A comparison between Figure 7 and 8 reveals that UAMA and UAFA 
followed a pattern of change more similar to FFMI and FMI as estimated by the equations 
of Durnin and Womersley (DW) than when the equations of Pollock et al. (Pol) are used. 
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Figure 8:  Fat mass index and fat free mass index as calculated by the equations of 
Pollock et al. (Pol) as well as by the equations of Durnin and Womersley (DW) for ART 
and TN groups at baseline and short term time points.  The symbol, a, indicates a 
significant interaction effect (p < 0.05).  The box plots represent mean ± SE, while the 
whiskers indicate ± SD.  Outliers are represented by an open circle (  ). 
 
However, the results generated from equations of Durnin and Womersley (DW) did not 
seem to show any changes over time for any of the groups, while those from the equations 
of Pollock et al. (Pol) indicate a significant group by time interaction for FFMI (see Figure 
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8, Panel C) and a trend for an increase in FMI for the TN group.  The Pol equation uses 
thigh skinfold when calculating the fat mass, whereas the DW equation does not. 
 
The data in Figure 9 indicate a significant interaction effect of group and time for the thigh 
skinfold (Panel A, main effect p < 0.05, post hoc difference at short-term p = 0.053), but 
not for thigh circumference (Panel B).  Thigh circumference tended to be different between 
the two groups, but this difference was not statistically significant (main effect p = 0.06).  
However, the tendency for thigh circumference to decrease but thigh skinfold thickness to 
increase in TN could imply a decrease in thigh muscle mass.  Indeed, this result is similar 
to the interaction effect between group and time for fat free mass corrected for height 
(FFMI, Pol) (p < 0.05), displayed in Figure 8 Panel C.  
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Figure 9:  Thigh skinfolds and circumferences at baseline and short term time points for 
ART and TN groups.  The symbol, a, indicates a significant interaction effect (p < 0.05).  
The box plots represent mean ± SE, while the whiskers indicate ± SD.  Outliers are 
represented by an open circle (  ). 
 
Another way of presenting these data, which removes the influence of individual 
differences in baseline body dimensions, is to calculate the change over time for each 
subject and then compare the two groups.  The change in thigh skinfold was again 
significantly different between the two groups (Figure 10 Panel A).  There was also a 
concomitant difference in fat free mass index (Pol) change.  These significant changes were 
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not reflected in BMI changes (Panel C), possibly because the change in FMI (Panel D) 
counteracted the change in FFMI. 
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Figure 10:  Changes of variables from baseline to short-term that indicate body fat and 
muscle mass content for ART and TN groups.  Vertical lines represent the SE and the 
symbol, *, indicate statistical significance, p < 0.05 (Mann-Whitney U test). 
 
In summary, the ART group did not improve significantly for any variables that relate to 
nutritional status or wasting (body mass related variables, %IAC, UAFA, UAMA FMI and 
FFMI) over the short-term phase, even though this group had significantly lower values 
than the TN group for some of these variables at baseline.  More dramatic changes were 
found for variables that may relate to lipodystrophy. 
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Initial ANOVA analysis showed that the interaction effect of group and time for the hip 
circumference approached statistical significance (p = 0.05), but this difference was not 
verified with post hoc analysis.  However, the Mann-Whitney U test revealed that the 
change in hip circumference was significantly different between the two groups during the 
short-term phase (p < 0.05).  Figure 11 illustrates comparisons between the groups for 
change in hip and waist circumference, abdominal skinfold and the calculated variable IAI.   
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Figure 11:  Changes of variables from baseline to short-term that relate to altered body 
fat deposition for ART and TN groups.  Vertical lines represent the SE and the symbol, 
*, indicate statistical significance, p < 0.05 (Mann-Whitney U test). 
 
Stellenbosch University http://scholar.sun.ac.za
 65
Although the means for the two groups was significantly different for change in hip 
circumference (see Figure 11, Panel A), there was no difference between the two groups for 
change in waist circumference (p = 0.66), or the change in abdominal skinfold.  The ART 
group also appeared to exhibit a change in mean IAI (Panel D), but this was not significant 
(p = 0.45).  An increased waist circumference can be the result of an increase in IAI or 
abdominal skinfold or both.   
 
However, the net effect of the variables presented in Figure 11 contributed to differences in 
the waist to hip ratio and the IAI to hip ratio.  As shown in Figure 12 Panels A and B, the 
change in W:H and IAI:H were significantly different between the two groups (p < 0.01; 
Mann-Whitney U test).     
 
These differences were confirmed when a strong interaction effect of group and time was 
found for W:H (p < 0.005) and IAI:H (p < 0.005) with the ANOVA analysis.  Post hoc 
analysis confirmed that W:H and IAI:H increased significantly (p < 0.05) during the short-
term phase in the ART group compared to the TN group.  
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Figure 12:  Changes of variables from baseline to short-term that relate to altered body 
fat deposition for ART and TN groups.  Vertical lines represent the SE and the symbol, 
*, indicate statistical significance, p < 0.01 (Mann-Whitney U test). 
 
* *
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The next section is devoted to the ART group only.  The results from comparisons relating 
to short-term and long-term time points are presented. 
 
5.4 ART group: short and long-term changes 
 
Follow-up information for CD4+ count and QoL was available for baseline the long-term 
time-point for the ART group.  CD4+ count and QoL improved significantly for the ART 
group (p < 0.05) (Figure 13). 
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Figure 13:  Individual CD4+ counts and QoL scores for the ART group at baseline and 
long-term time points.   
 
Although most variables showed an upward trend for the ART group (especially during the 
long-term phase, e.g. Figures 14 and 15), these trends were generally not significantly 
different at the short-term or long-term time points compared to the baseline time-point.  
When considering the variables that indicate nutritional status such as %IBW and %IAC, 
both follow an upward trend (p = 0.18 and p = 0.29 respectively) – especially after the 
short-term point.  It can also be seen from Figure 14 that the inter-individual variation 
seemed to have decreased for percent of ideal body weight, but not for the variable that 
involved measurements of the arm (percent of ideal arm circumference). 
 
Stellenbosch University http://scholar.sun.ac.za
 67
 
A B ART participants   
baseline short-term long-term
70
80
90
100
110
120
130
140
150
160
Pe
rc
en
t o
f i
de
al
 b
od
y 
w
ei
gh
t (
%
) 
 baseline short-term long-term
50
60
70
80
90
100
110
120
130
140
150
Pe
rc
en
t o
f i
de
al
 a
rm
 c
irc
um
fe
re
nc
e 
(%
) 
 
Figure 14:  Box plot representation of variables that indicate nutritional status the ART 
group at baseline, short term and long-term time points.  The box plots represent mean ± 
SE, while the whiskers indicate ± SD.  Outliers are represented by an open circle (  ). 
 
Arm fat (UAFA) and muscle (UAMA) area also tended to increase over time (especially 
after the short-term time-point) for the ART participants, although none of these increases 
proved to be statistically significant (ANOVA: p = 0.38 and p = 0.21, respectively) (Figure 
15). 
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Figure 15:  Upper arm fat (UAFA) and muscle (UAMA) areas for the ART group at 
baseline, short term and long-term time points.  The box plots represent mean ± SE, 
while the whiskers indicate ± SD.  Outliers are represented by an open circle (  ). 
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It is clear from the data in Figure 15 that outliers are present at each time point and the SD’s 
are large.  The outliers at baseline and short-term for UAFA are from participant ART1, 
while the outlier value at the long-term time-point represents participant ART4.  There was 
also a dramatic shift for ART4 regarding UAMA values.  ART4’s UAMA value was the 
lower limit outlier at the short-term time-point and the higher limit outlier at the long-term 
time-point.  The two higher limit outliers at baseline and short-term for UAMA represent 
data of participant ART2.   
 
One method to descriptively display the data is to show the number of observations that fall 
into categories that relate to population percentile values.  The calculated UAMA and 
UAFA of the participants were categorized according to percentile categories of Frisancho 
(1981) (see Figure 16). 
 
At baseline most (50%) subjects’ UAMA fitted into the main category (25th – 75th 
percentile).  There were fewer UAMA and UAFA observations in the two lowest categories 
(“5th ≤ and < 25th” and the “less than 5th”category) at the long-term time-point compared to 
the baseline and short-term time points, suggesting an eventual improved nutritional status 
over time after initiation of ART in this small group of subjects. 
 
Three participants had UAMA values that were classified below the 25th percentile at 
baseline.  Two of these were below the 5th percentile.  At the short-term time-point, one 
participant’s nutritional status worsened and there were 4 observations below the 25th 
percentile.  Yet, at the long-term time-point, only one participant’s UAMA value was still 
classified below the 25th percentile, indicating improved arm muscle content for at least two 
participants. 
 
Although less dramatic, there was also a shift to the right for the UAFA values over the 
long-term phase.  One participant’s UAFA value worsened during the short-term phase 
resulting in three observations below the 5th percentile at the short-term time-point.  Only 
one observation remained in this category at the long-term time-point. 
 
Stellenbosch University http://scholar.sun.ac.za
 69
A ART group at baseline 
0 
1 
2 
3 
4 
5 
6 
< 5th 5th  25th 25th 75th 75th 95th 95th 100th
Percentile category
Fr
eq
ue
nc
y 
(n
um
be
r o
f o
bs
er
va
tio
ns
) 
 
 
     UAMA 
     UAFA 
B ART group at the short-term time-point 
0 
1 
2 
3 
4 
5 
6 
< 5th 5th  = and < 
25th 
25th = and
<75th
75th = and
<95th
95th = and
<100th
Percentile category
Fr
eq
ue
nc
y 
(n
um
be
r o
f o
bs
er
va
tio
ns
) 
 
C ART group at the long-term time-point 
0 
1 
2 
3 
4 
5 
6 
< 5th 5th  = and < 
25th 
25th = and
<75th
75th = and
<95th
95th = and
<100th
Percentile category
Fr
eq
ue
nc
y 
(n
um
be
r o
f o
bs
er
va
tio
ns
) 
 
Figure 16:  Histograms of upper arm muscle (UAMA) and fat (UAFA) areas according 
to population percentile categories for the ART group at baseline (n = 8), short-term (n = 
8) and long-term (n = 7) time points. 
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At the long-term time-point, there were more UAFA observations below the 25th and 5th 
percentile categories than for UAMA.  While only one participant had a UAMA value less 
than the 25th percentile value (and no participant’s UAMA was below the 5th percentile) at 
the long-term time-point, there were 4 UAFA observations lower than the 25th percentile 
and 1 of these was lower than the 5th percentile.   
 
In summary, the ART group’s UAMA values were generally higher than their UAFA 
values when compared to population percentiles.  At least one participant showed a 
worsening of arm area measures at the short-term time-point while a general improvement 
was apparent for the whole group at the long-term time-point.  Whether such a trend would 
occur in a larger cohort remains to be determined. 
 
Despite the fact that upper arm fat mass appeared to be affected negatively by HIV status 
relative to population norms, Figure 17 suggests that there was a general increase in the 
triceps and biceps skinfold thickness from baseline and short-term to the long-term time-
point.  Similar trends were seen for other skinfold thicknesses, although only the supra-
illiac skinfold at long-term was statistically significantly different (p < 0.05) from the 
baseline value. The ART group’s sub-scapular skinfold tended to change from baseline to 
long-term (p = 0.07) and from short-term to long-term time-points (p = 0.08) after 
performing a Bonferroni correction. 
 
Figure 18 shows that the same upward trend is apparent for thigh skinfold and thigh 
circumference (although none of these variables changed significantly).  Although both 
FMI (Pol) and FFMI (Pol) also followed an upward trend, these variables did not change 
significantly during the study.  FMI and FFMI as calculated from the equations of Durnin 
and Womersley (1974) followed a similar trend to that of FMI (Pol) and FFMI (Pol) (data 
not shown). 
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Figure 17:  Skinfolds that are used to indicate changes in muscle and fat mass for the 
ART group at baseline, short term and long-term time points. * indicates statistical 
significance, p < 0.05.  The box plots represent mean ± SE, while the whiskers indicate ± 
SD.  Outliers are represented by an open circle (  ). 
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Figure 18:  Changes in muscle and fat mass for the ART group at baseline, short term 
and long-term time points.  The box plots represent mean ± SE, while the whiskers 
indicate ± SD.  Outliers are represented by an open circle (  ). 
 
Figure 19 and 20 provide information about variables that are related to waist 
circumference, since changes in the latter may be a result of an altered fat deposition or an 
increase in intra-abdominal fat, or both.  Although the waist circumference of the ART 
group did increase significantly from the baseline to the long-term time-point (p < 0.05), 
hip circumference also appeared to be raised at the long-term time-point.  Therefore, waist-
to-hip ratio of the ART group appeared to deviate from the pattern of gradual increase that 
is evident for the other variables shown in Figures 14, 15 and 17.   
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Figure 19:  Box plot representation of variables related to altered fat deposition for the 
ART group at baseline, short term and long-term time points.  * indicates statistical 
significance, p < 0.05.  The box plots represent mean ± SE, while the whiskers indicate ± 
SD.  Outliers are represented by an open circle (  ). 
 
In summary, several variables indicate increased fat mass; however, it is important to 
determine if increases in fat mass are evenly distributed or not.  The intra-abdominal 
indicator measure showed a gradual non-significant trend toward an increase for the 
ART group (p = 0.12) (Figure 20). 
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Figure 20:  Box plot representation of additional measures that may indicate altered fat 
deposition for the ART group at baseline, short term and long-term time points.  * 
indicates statistical significance, p < 0.05.  The box plots represent mean ± SE, while the 
whiskers indicate ± SD.  Outliers are represented by an open circle (  ). 
 
However, taking into account the percentage of ideal body mass (%IBW) and percentage 
of ideal arm circumference (%IAC), %IBW/%IAC increased significantly from the 
short-term time-point to the long-term time-point.  This indicates that the %IBW 
increased more than the %IAC over this time-period. 
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Discussion 
 
Undertaking longitudinal research in a semi-rural setting in a South African clinic presents 
numerous obstacles, some of which were known prior to the study e.g. requirement for 
cost-effectivity.  The TN group was a poor control group since they were not a homogenous 
group with respect to disease stage and they were poorly matched to the ART group with 
regard to body mass and CD4+ count.  More suitable control groups should be used for 
future studies, including ethnically and socially relevant HIV-negative control groups. 
 
The following points summarize the main findings. 
1) Statistical analysis indicated that TN and ART participants did not differ 
significantly for many variables at baseline. 
a. This was influenced by the large inter-individual variation in both groups as 
well as small group sizes. 
b. The major differences between ART and TN were observed in 
measurements of the arm, especially %IAC and UAFA, which were 
significantly lower in ART at baseline because on average their disease 
progression was more advanced.  Related to this is the fact that 6 of the 8 
ART participants were categorized as having UAFA less than the 25th 
percentile. 
2) CD4+ count and QoL improved significantly for the ART participants from 
baseline to long-term.  Associations with changes in muscle mass and fat mass 
variables were difficult to confirm due to low subject numbers. 
3) A significant interaction effect between group and time was found for thigh 
skinfold and FFMI (Pol), but no significant improvements or declines were found 
for any variables related to wasting status for either group in the short term. 
4) Participants on antiretroviral medication exhibited changes in abdominal 
anthropometric measurements or calculated variables: 
a. ART vs. TN group comparisons at baseline and short-term: 
i. The W:H and IAI:H of ART participants increased significantly 
compared to the TN group. 
b. ART group comparisons at baseline, short-term and long-term: 
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i. Supra-illiac skinfold increased significantly from baseline to long-
term. 
ii. Two measures that may be related to lipodystrophy increased over 
time (waist circumference and %IBW:%IAC). 
 
Disease progression and wasting will be discussed in the first section, while the second 
section will be devoted to lipodystrophy issues.   
 
5.5 Disease progression and wasting 
 
The most commonly used indicator of disease progression in an individual with HIV 
infection is the CD4+ count (Weatherall et al., 1996).  Other indicators are viral load and 
CD4 to CD8 ratio (Ray et al., 2006; Rodriguez et al., 2006).  A CD4+ count below 350 
cells/μL is considered to be one of the criteria that signify the need for treatment initiation 
in the USA (Baylor College of Medicine, 2003), although the value in South Africa is a 
count below 200 cells/ μL. Although the CD4+ counts of the two groups were not 
significantly different at baseline regarding (p = 0.09), a large inter-individual variation was 
apparent for the TN group.  Two of these participants could have qualified for treatment at 
the time of recruitment, but treatment was not yet available before 2004.  Therefore, the 
participants that were recruited before 2004 were classified into the TN group, although 
that classification does not imply that they did not yet qualify for treatment.  A difference 
did emerge however when the CD4+ counts were categorised according to the CDC 
immune category.  Therefore, the ART group was in fact as a whole at a more advanced 
stage of the disease than the TN group.  The fact that the two groups differed with regard to 
measures of the arm, suggests that arm measures may be indicative of disease progression 
(discussed in more detail later in this section). 
 
For four (29%) of the participants (including both the ART and the TN participants), the 
CD4+ counts were determined more than 3 months before or after the anthropometry 
measurements were done.  Therefore the TN and ART groups’ CD4+ counts at baseline 
may not be an accurate reflection of their clinical status at that time.  For example, The 
CD4+ counts of two ART participants were determined more than seven months prior to the 
Stellenbosch University http://scholar.sun.ac.za
 77
baseline anthropometry measurements.  Their CD4+ counts were 393 and 160 respectively.  
Considering the fact that they were included into the treatment programme, it is 
conceivable to surmise that their CD4+ counts may have been lower at the baseline time-
point, but lower values were not recorded in the patient files. 
 
An American source of treatment guidelines recommended that (due to variability of CD4+ 
counts) two to three baseline CD4+ counts should be determined before initiating 
antiretroviral treatment (Department of Health and Human Services, 2005).  It was also 
stated that CD4+ counts should be taken every three to six months to monitor patients.  As 
can be inferred from the previous paragraph – such practices are not always possible in 
developing countries at the level of rural clinics.  Therefore, undertaking observational 
research in such a rural environment is often accompanied with certain restrictions and 
considerations relating to cost-effectiveness that are unique to the setting.  In addition, the 
effectiveness of time utilisation and space availability are two other important 
considerations for conducting research in rural clinics.  
 
Another factor that is related to disease progression is wasting status (Baylor College of 
Medicine, 2003).  The loss of body mass is one of the criteria used in the WHO staging 
system (see section 2 for more information on this staging system).  However, whether or 
not this is applicable in South Africa has never been investigated.  As mentioned in the 
literature review, the HIV wasting syndrome is an AIDS defining condition called the 
AIDS wasting syndrome (AWS).  It is also possible to have other AIDS-defining criteria in 
the absence of wasting.  Several criteria defining the extent of wasting required to fulfil the 
definition have been developed: involuntary body mass (BM) loss greater than 10%, 
unexplained chronic diarrhoea for more than one month associated with BM loss, or 
weakness and unexplained prolonged fever for more than one month (Baylor College of 
Medicine, 2003; Nemechek et al., 2000; CDC, 1992).   
 
As discussed in the literature review, BM can provide useful information regarding the 
physiological status of an HIV-infected individual.  BMI and %IBW are therefore also 
important variables, since they represent the BM after taking into account the height of the 
individual.  Since the term malnutrition refers to the loss of structural body components, 
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one or more parameters of malnutrition can be used as complementary standards of 
objectively assessing wasting.  Although, in terms of body measurements, malnutrition is 
most accurately reflected by the body cell mass (BCM) (Ott, et al. 1993), I examined more 
cost-effective accepted indicators of malnutrition (%IBW and threshold values that relate to 
arm variables) to assess wasting or lack thereof.  Population percentiles were also used to 
compare the participants to a large database of individuals of a similar age group 
(Frisancho, 1981). 
 
At baseline the percent of ideal body mass (%IBW) of the TN participants ranged from 98 
to 176% with an average of 137%, while the ART group’s %IBW ranged from 67 to 153% 
(refer to Table 5). 
 
According to the definition of the AWS, a formal diagnosis can only be made by assessing 
body mass loss over time as well as taking into consideration the presence of associated 
conditions like diarrhoea, fever and weakness.  In the absence of firm longitudinal data and 
community relevant controls it is difficult to make any assumptions on what the ideal body 
weight of the HIV-infected subjects in the study should be.  Nonetheless, generalized 
norms are available for ideal body weight (Baylor College of Medicine, 2003), which were 
used to calculate an estimated IBW taking height into account.   
 
It should also be noted that many infected individuals have an initial body mass much 
greater than 100% (eight of the nineteen recruited participants had a %IBW greater than 
110%).  Individuals such as these could be undergoing wasting without having a body mass 
less than 10% of the ideal.  For example, one participant was classified with late stage 
disease (WHO stage 4) and her calculated muscle area was below the 5th percentile 
threshold, but her body mass was only 1 percent below the ideal prescribed for a female of 
her height.  Therefore, in a rural South African setting, taking only BM into consideration 
when evaluating a patient with regard to wasting is insufficient.  However, recording 
accurate monthly BM measurements will have the benefit of providing longitudinal 
information although not specific to body compartments.   
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A body mass index below 18.5 has been suggested as a general threshold that may indicate 
being underweight for adults (WHO Technical Report, 2000).  A body mass index less than 
20 and a body mass less than 90% of estimated ideal body mass have been suggested to 
indicate malnutrition for an adult (Baylor College of Medicine, 2003).  Another resource 
defined malnutrition as marginal when the BMI falls between 18.5 and 20, mild when the 
BMI falls between 16 and 17 and severe when it is below 16 (Weatherall, et al. 1996).  
According to these criteria, one of the ART participants can be said to have had severe 
malnutrition.  One participant was mildly malnourished, while four of the ART participants 
had BMI’s between 18.5 and 20.  None of the TN participants’ BMI’s was below any of 
these limits.   
 
The participant with severe malnutrition also exhibited the symptoms of diarrhoea and 
weakness.  She was the only participant to be clinically diagnosed as being wasted by the 
medical staff at the clinic.  Another participant weighed 58.2 kg at the time of recruitment.  
She reported experiencing occasional diarrhoea, fever, weakness and body mass loss.   
 
The graphs shown in Figure 21 clearly indicate an improvement of BMI for the ART 
participants.  Even though 50% of the ART participants had BMI under the “BMI of 20 
threshold” at baseline, none of these participants were classified below any of the threshold 
values related to body mass relative to height at the long-term time-point.  All the TN 
participants were above the thresholds at baseline as well as short-term, suggesting that 
none of the TN group were malnourished. 
 
Another indicator of malnourishment is having a mid upper arm circumference (also 
referred to as MUAC, but abbreviated as AC for the current study) less than 22 cm 
(Weatherall, et al. 1996).  The two groups differed in their %IAC as well as UAFA, but not 
any of the other anthropometry variables.  This may indicate that a decrease in arm 
circumference (involving especially the arm fat) may be an early manifestation of advanced 
disease progression.  Should this finding be replicated in a larger cohort, it may present the 
possibility of application in the rural clinics involved in monitoring patients.   
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Figure 21:  Variables related to BM in ART and TN groups at baseline (Panel A), short 
term (Panel B) and long-term (Panel C) time points.  Estimated %IBW was calculated 
taking into account height (Baylor College of Medicine, 2003). 
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The %IBW, %IAC, UAFA and UAMA variables did not improve significantly for the ART 
group over time. Since the statistical analyses rely on means and standard deviations and 
because of the small subject numbers, it is also necessary to briefly discuss individual data.  
(See Appendix E for the graphs.)  Although most of the ART participants showed a gradual 
increase for anthropometry variables and one ART participant showed a dramatic increase, 
two participants tended to have decreased values, especially at the long-term time-point.  
These observations indicate the requirement for greater subject numbers in order to 
subdivide subjects according to groups with different responses. 
 
Classifying the ART and TN groups according to their arm anthropometry values (Figures 
22 and 23) revealed the same pattern as that shown in Figure 21.  Three of the four ART 
participants with low BMI values also had arm muscle area values below the 25th percentile 
threshold, while all four of them had arm circumference and fat area values below the 25th 
percentile threshold.  It seems that the “BMI of 18.5” and “%IBW of 90” criteria lead to a 
more similar classification to the “AC of 22” criterion than does the criterion of “BMI of 
20”.  Using a BMI of 20 as threshold value is possibly therefore not selective enough. 
 
The same conclusion could be made about using a threshold of less than the 25th percentile 
to classify percentile values of arm circumference (AC), triceps skinfold (TS), upper arm 
fat area (UAFA) and upper arm muscle area (UAMA).  The population standards are not 
generated exclusively from individuals living a rural or semi-rural lifestyle and also not 
individuals from the population groups in this study.  This might be the reason why so 
many participants (even from the TN group) are classified below the chosen threshold in 
Figure 23.  Those that are included into the less than 25th percentile but not the 5th 
percentile are possibly erroneously included into a class that indicates malnutrition.  
Alternatively, it could be a more sensitive indicator of future manifestation of malnutrition. 
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Figure 22:  Variables related to the arm indicating the number of subjects in the lowest 5th 
population percentile or with an arm circumference of 22 cm in ART and TN groups at 
baseline, short-term and long-term time-points. 
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Figure 23:  Variables related to the arm indicating the number of subjects in the lowest 
25th population percentile or an %IAC of 90 in ART and TN groups at baseline, short-
term and long-term time-points. 
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It is possible that participants may experience wasting before it is becoming apparent from 
BM status.  In a clinical setting, follow-up measurements would be vital for such patients 
(especially those not on treatment yet) to establish whether they are merely thin or are 
starting to experience wasting and a decline in health.  After conducting a study that 
compared the measurements of South African youths with youths from other ethnic groups, 
Eckhardt et al. (2003) suggested that anthropometry measurements should be considered in 
conjunction with BMI when assessing body composition and that these assessments can be 
influenced by ethnicity. 
 
Performing anthropometry measurements on the arm is a simple and cost-effective 
assessment that can be made on a routine basis.  At baseline triceps skinfold thickness 
correlated positively with CD4+ count in ART and TN subjects combined (R = 0.71; p = 
0.02).  This and other related variables should be investigated in a larger study group.  
Values obtained from measuring the arm circumference and subcutaneous fat content could 
provide important objective additional information about the nutritional status of the 
patient.  This indirect evaluation of the nutritional status of the patient in conjunction with 
clinical evidence could provide the necessary information to confirm wasting at an early 
stage. 
 
The TN participants in our study did not exhibit a decrease in arm measures during the 
short-term phase.  Long-term changes may however be different.  Nevertheless, some of the 
TN participants’ arm variables were below the 25th percentile threshold (Figure 23) but not 
the 5th percentile threshold (Figure 22).  Therefore, using the 25th percentile (or a threshold 
between 5 and 25) as threshold level to indicate nutritional status may serve as an early 
warning sign of future malnutrition.  This could only be assessed by further longitudinal 
studies with ethnically diverse study groups. 
 
A closer look at the QoL data can provide further indication regarding the status of the 
ART and TN participants.  Figure 4B indicates an outlier in the ART group with a 
particularly low overall QoL score. Although the sample size was too small to perform 
meaningful statistical analysis on the sub-divisions of QoL, some information can be 
gained from looking at the pie charts shown in Figure 5.  One ART participant was 
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consistently reporting severe problems, but this subject did not coincide with the subject 
with the lowest (outlying) overall score. This indicates that the overall score is perceived 
differently from the more specific questions.  
 
The TN participants did exhibit some problems with all except the self-care QoL 
dimension.  After a closer look, it was clear that these problems were not experienced only 
by subjects who actually already qualified for ART, but were not receiving it.  It is possible 
that these problems are unrelated to the progression of the HIV-infection, or that the 
observations arose out of experimental error (e.g. difficulty in asking questions through 
translation).  However, if some of the TN participants did experience problems with 
mobility, pain, performing usual activities and anxiety (as indicated in Figure 5) as a result 
of the HIV-infection, it is possible that they were already experiencing some side effects of 
wasting or some other condition related to disease progression.  Alternatively the diagnosis 
itself may have caused sufficient anxiety to disrupt QoL.   
 
In summary, using anthropometry variables of the arm to observe patients may present an 
alternative way of monitoring wasting.  It is a practical cost- and time-effective method that 
nurses could easily do in rural clinics.  Population reference values could be supplied to 
clinics as wall charts to make the process easier.  Although the information supplied by 
publications such as Frisancho (1981) can be used initially, reference values relevant to 
South African populations should eventually be produced and used.  Further research is 
merited, especially an investigation into the predictive value of using a threshold between 
the 5th and 25th percentile that could foretell future malnutrition in patients. 
 
It is interesting to note that those measures that relate specifically to fat (TS and UAFA) 
tend to have a greater frequency below the chosen thresholds than UAMA. It is possible 
that this indicates a preferential loss of fat instead fat free mass similar to that seen in other 
studies (Kotler et al., (1999); Swanson et al., (2000)).   
 
It is also recommended that future research should include measurements of QoL and 
physical functioning.  Such observations should be interpreted in relation to anthropometric 
measurements since important recommendations can be made from such information.  For 
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example, it is possible that those patients that manage to stay active can maintain their 
muscle mass better than those individuals that do not.  Therefore, I have made a preliminary 
investigation into possible ways of assessing physical functioning in a resource-poor and 
space-limited clinical setting (refer to Appendix B). 
 
Lipodystrophy 
 
Lipodystrophy results in the preferential deposition of fat in the intra-abdominal area.  Less 
fat is deposited in peripheral areas like the arms and legs, or fat may be mobilized from 
these areas.  Therefore, the fat deposited in the intra-abdominal area could be a result of 
redistribution (McDermott et al., 2001) of existing fat in the body (patients who were not 
malnourished before these changes) or the preferential deposition of “new” fat in intra-
abdominal areas in patients who gained body mass after being malnourished.  
 
Mechanisms for targeting of peripheral fat in patients include the impairment of the 
mitochondrial DNA polymerase γ (with NRTI administration) and inhibition of the 
cytochrome P450-3A isoform (with PI administration) that may interfere with retinoic acid 
binding and lead to impaired adipocyte function,  adipocyte differentiation, decreased 
storage of triglycerides, insulin resistance and apoptosis (Hirsch & Battegay, 2002).  
Further research into whether or not women differ from men in their responses to ART 
should be done. 
 
 In order to exclude possible confounding effects of body mass loss (e.g. causing a decrease 
in arm fat) only weight stable patients were included in some of the lipodystrophy studies 
mentioned in the literature review (Rodwell et al., 2000; Carr et al., 1999; Gervasoni et al., 
1999).  Therefore, these studies only investigated the redistribution of existing fat reserves.  
However, in a different study, patients with lipodystrophy have also shown a highly 
significant loss of body mass (p = 0.0005) in comparison to a control group (Carr et al., 
1998). 
 
 Change in waist circumference represents the cumulative effect of the change in IAI and 
abdominal skinfold.  The pattern of changes of the TN group’s IAI and abdominal skinfold 
Stellenbosch University http://scholar.sun.ac.za
 87
suggests that the change of the one variable negated the changes of the other variable, 
resulting in a relatively unchanged waist circumference. 
 
However, changes in waist circumference could also be accompanied by changes in hip 
circumference, thus one or both of these variables could influence the parameters of W:H 
and IAI:H.  The significant increase of W:H and IAI:H observed in the ART group 
compared to the TN group may be a result of an increased deposition of intra-abdominal 
fat.  In a group where some participants started out as being malnourished and subsequently 
improved their nutritional status, it is difficult to establish to what extent this increase is 
influenced by changes relating to “gaining weight”, as opposed to redistribution of fat 
mass.  
 
If the subcutaneous fat had increased more in the abdominal area than the gluteal area, this 
could explain the increased W:H observed.  It would however not explain an increase in 
IAI:H.  IAI exhibited a gradual non-significant increase over time (Figure 20, Panel A).  A 
combined effect of an increase in body mass and a redistribution of body fat with fat now 
being stored intra-abdominally and subcutaneously (only the latter expected with normal 
weight gain) may have contributed to the increase in waist circumference observed in the 
ART participants over the long-term.    
 
“Gluteal wasting” has also been reported to be associated with lipodystrophy (Salomon et 
al. 2002; Carr et al. 1999; Gervasoni et al. 1999); therefore there could be opposing effects 
on the hip circumference.  An increase in body mass could lead to an increase in hip 
circumference, while peripheral wasting could result in a decreased hip circumference.  The 
use of dual X-ray absorptiometry (DXA) to measure total or regional fat content could be a 
useful method in assessing the redistribution of body fat (HIV Lipodystrophy Case 
Definition Study Group, 2003).   
 
The female body also tends to store fat more easily in the gluteal area than some other areas 
of the body (Blaak, 2001), which could mask the manifestation of lipodystrophy in women.  
Therefore, it is possible that lipodystrophy should be investigated in a different way in men 
and women.  Using arm anthropometry variables to indicate lipodystrophy could also offer 
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an alternative method of monitoring lipodystrophy-related changes.  However, being able 
to discriminate such changes from the changes seen in wasting will pose a significant 
challenge. 
 
Table 9:  Body composition changes associated with wasting and lipodystrophy. 
Change as a result of 
Variable 
wasting recovering from wasting lipodystrophy 
Waist circumference ↓ ↑ ↑ 
Intra-abdominal indicator ↓ ↑ ↑ 
Hip circumference ↓ ↑ ↓ 
Arm circumference ↓ ↑ ↓ 
 UAMA ↓ ↑ - 
UAFA ↓ ↑ ↓ 
↑ symbolize an increase; ↓ symbolize a decrease; - indicates that there is no plausible effect on this variable. 
 
Body composition changes of HIV-infected patients are therefore complex and multifaceted 
(Table 9).  This may be why no statistically significant changes were observed for the ART 
participants with regard to the waist and intra-abdominal indicator to hip ratios when these 
data were analyzed over the long-term.  Other possible explanations are that the statistical 
power (group size) was too small or that even the long-term time point is still an early time 
point for lipodystrophy to develop in patients taking ART.  The longitudinal study 
conducted by Galli et al., (2003) found evidence of fat accumulation and combined forms 
(simultaneous evidence of fat loss and fat accumulation) in HIV+ women receiving 
antiretroviral therapy after 12 months of observation, with more observations (especially 
lipoatrophy) after 24 months. 
 
It is also possible that a patient could be experiencing only lipoatrophy, without the 
concomitant increase in waist circumference.  In the study conducted by Rodwell et al. 
(2000), which investigated patients with a clinically abnormal reduction or absence of 
subcutaneous tissue in the cheeks, data revealed that 6 of 14 participants exhibited 
decreased fat in the cheeks without an enlarged abdomen.  Five of the participants exhibited 
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clinically abnormal absence or reduced fat in the legs and arms without an enlargement in 
the abdomen.  Another study (Carr, et al. 1998) showed that patients receiving protease 
inhibitors had lower arm and leg fat mass but similar central abdominal fat mass compared 
to control patients. 
 
Figures 22 and 23 illustrate that there is still some evidence for sub-optimal arm fat 
reserves at the long-term time point, while arm muscle areas compared better to healthy 
population values.  It is possible that this could be a manifestation of peripheral arm fat loss 
in some participants as a result of lipodystrophy.  Therefore, changes in arm fat mass 
(interpreted according to population reference values (Frisancho, 1981)) could also be used 
as an additional measure when assessing lipodystrophy.  Once again, more participants 
were included under the 25th percentile threshold than the 5th percentile threshold and it is 
possible that the 25th percentile is too lenient to be clinically relevant.  Subsequent studies 
should investigate the use of arm fat percentile values as an additional variable when 
assessing lipodystrophy.  However, this should be done in conjunction with arm muscle 
area to take into account the possibility that wasting could be affecting the arm fat instead. 
 
In our study there was a greater increase in %IBW than %IAC which may be a normal 
manifestation of “gaining weight” or it may also be an indicator of lipodystrophy.  Patients 
who are weight stable, yet show an increase in %IBW to %IAC ratio may be experiencing 
peripheral wasting and fat redistribution.  The changes in this ratio (%IBW:%IAC) could 
therefore also be a helpful variable when assessing lipodystrophy and should be considered 
in future studies. 
 
6.3 Conclusions 
 
The increased CD4+ counts of the ART participants and the information gained from the 
QoL questionnaires suggest that their health improved.  The general trend of increasing 
skinfold and other anthropometric values suggests that the ART group gained body mass, 
which consisted of both fat and fat free mass.  If the sample size had been larger, more of 
these variables might have shown a statistically significant increase.  Antiretroviral therapy 
seemed to contribute greatly to the QoL of the participants and it probably aided in the 
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recovery from wasting for at least one participant in this study.  Attempts to understand 
changes in the anthropometry of the arm could lead to recommendations for use in a 
clinical setting to effectively monitor patients in future.   
 
This study found some evidence of lipodystrophy even though a very small sample group 
was investigated.  Two new calculated variables (IAI and %IBW:%IAC) were derived and 
investigated that could make the monitoring of lipodystrophy easier.  These variables are 
not tested or validated and should be included in future studies to examine the feasibility of 
using them in a clinical environment.   
  
Finally, continuation of this study could add to the literature on responses to ART in 
Southern Africa.  It is possible that different ethnic groups can exhibit different metabolic 
responses which can lead to different changes in body composition (Punyadeera et al., 
2001).  Although studies that investigate different metabolic responses and differences in 
body composition in specific ethnic groups from Southern Africa are available (van der 
Merwe et al., 1998; Punyadeera et al., 2002; Kruger et al., 2004), I could not find any 
studies that specifically investigates the effect of ART on the body composition of South 
African women.  Such investigations would be important since it has been shown that 
obese South African black women are more insulin resistant than obese South African 
white women (van der Merwe et al., 2000), which could predispose these black women to 
develop type 2 diabetes (van der Merwe et al., 2001).  Other metabolic differences like 
higher concentrations of leptin and free fatty acids have also been shown in obese South 
African black women (van der Merwe et al., 1999).  A better understanding of how these 
processes differ between ethnic groups may lead to improved treatment and lifestyle 
interventions in South African populations.   
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Appendices 
 
7.1. Appendix A 
 
Defining AIDS 
 
The following definitions were taken from Weatherall et al. (1996). 
 
The 1987 CDC (Centers for Disease Control) definition of AIDS states that it is an illness 
characterized by one or more ‘indicator’ diseases.  When the following indicator diseases 
are diagnosed in the absence of another cause of immune deficiency even without 
laboratory evidence of HIV infection – they are considered to be indicative of AIDS: 
– Candidiasis: oesophageal, pulmonary 
– Cryptococcosis: extrapulmonary 
– Cytomegalovirus disease: disseminated 
– Herpes simplex virus infection 
– Mucocutaneous ulceration lasting longer than 1 month 
– Pulmonary or oesophageal infection 
– Kaposi’s sarcoma: patient aged under 60 
– Primary cerebral lymphoma: child aged under 13 
– Mycobacterium avium: disseminated 
– Mycobacterium kansasii: disseminated 
– Pneumocystis carinii pneumonia 
– Progressive multifocal leucoencephalopathy 
– Cerebral toxoplasmosis 
If there is laboratory evidence of HIV infection and the following indicator diseases are 
either definitively or presumptively diagnosed (regardless of the presence of other causes of 
immune deficiency) – a diagnosis of AIDS can be made: 
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Diseases diagnosed definitively: 
– Recurrent/multiple bacterial infections: child aged under 13 
– Coccidioidomycosis: disseminated 
– HIV encephalopathy 
– Histoplasmosis: disseminated 
– Isosporiasis: diarrhoea persisting for longer than 1 month 
– Kaposi’s sarcoma at any age 
– Primary cerebral lymphoma at any age 
– Non-Hodgkin’s lymphoma: diffuse undifferentiated B-cell type, or unknown 
phenotype 
– Any disseminated mycobacterial disease caused by other than 
Mycobacterium tuberculosis 
–  Mycobacterium tuberculosis: extrapulmonary 
– Salmonella septicaemia: recurrent 
– HIV wasting syndrome 
Diseases diagnosed presumptively: 
– Candidiasis: oesophageal 
– Cytomegalovirus retinitis with loss of vision 
– Kaposi’s sarcoma 
– Lymphoid interstitial pneumonia: child aged under 13 
– Mycobacterial disease (acid-fast bacilli, species not identified by culture): 
disseminated 
– Pneumocystis carinii pneumonia 
– Cerebral toxoplasmosis 
Since 1993 another definition of AIDS has been used in the United States.  According to 
this definition any person with a proven HIV infection with a CD4+ lymphocyte count of 
less than 200 cells/μl is diagnosed with AIDS (irrespective of clinical manifestation).  
Three new AIDS-indicator diseases were also added to the above list.  These are pulmonary 
tuberculosis, recurrent bacterial pneumonia in adults and invasive cervical cancer. 
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The World Health Organization (WHO) also proposed other definitions for use in 
developing countries.  These include the Bangui (for use in sub-Saharan Africa) and 
Caracas (the Pan American Health Organisation and the WHO Global Programme for 
South America) definitions (WHO, 2004).  
 
7.2. Appendix B 
 
Physical activity: 
 
Disease can lead to a decrease in physical activity and it is possible that this decrease in 
activity can impact negatively on conditions like wasting and lipodystrophy.  It is important 
for future researchers to investigate the interaction between disease, physical activity and 
QoL in HIV/AIDS, since these three aspects probably interact in a reciprocal and complex 
manner.  
 
Although I originally wanted to measure the physical mobility and fitness of the 
participants in this study, it became clear early on that there were a few obstacles unique to 
a clinical environment in South Africa that would make this endeavour difficult.  At the 
time of doing this study, this population group was unfamiliar with researchers conducting 
studies and they were reluctant to join in the project.  Although the participants that 
eventually joined this study did so voluntarily after all their questions were answered and 
the project was discussed at great length before starting any measurement, they were still 
inherently hesitant to participate in unfamiliar activities.  Therefore I focussed on 
measurements like anthropometry (which more closely resembles a nurse or doctor’s 
consultation).  I did however perform a few tests that could give an indication of muscular 
and cardiovascular physical fitness.  These tests were easy to perform and the participants 
were not hesitant to participate in these tests, since care was taken in the design of the tests 
to exclude actions or equipment they were not familiar with.  All the participants of the 
“study group” that participated in exercise tests had been on ART for at least 9 months.  
Two of the tests (the Bottle Test and the Grip Strength Test) were also carried out by a 
“control group” of 76 female students who were between the ages of 20 and 25 years. 
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Bottle Test: 
 
Existing muscular endurance tests that require the participant to do sit-ups, chin-ups, push-
ups dips and squats were thought to be too unfamiliar to be performed by this population.  
Some of these tests also require the use of expensive equipment, which makes them less 
feasible for implementation in a South African clinic setup.  The “Bottle Test” was 
designed to be a practical test for a clinical environment, requiring no expensive equipment 
or specific skill for performing the test.   
 
The test consists of incremental workloads to exhaustion.  Instead of traditional weights, 
filled 1-litre water bottles (each weighing 1 kg) were put inside two strong shopping bags.  
At first, each bag contained 3 bottles (3 kg), after which bottles were added for each 
subsequent level with increments of 3 kg per bag.  To perform the test, the test subject was 
required to sit upright on a chair with no armrests, while holding the arms flexed at an angle 
of 90º at the elbow.  The test administrator then held the bags so that the participant could 
easily get a hold on them, one in each hand.  A timer was started when the test 
administrator transferred the weight of the bags to the hands of the participant.  The test 
administrator recorded the duration that the participant could hold the bags while 
maintaining an angle of 90º at the elbow for that arm.  (Separate scores were recorded for 
the right and the left arm.)  The administrator stopped the participant if a time of 3 minutes 
were reached, signifying the completion of that level.  After a rest lasting 5 minutes and 
adding 3 bottles to each bag, the next level was then attempted.  Once a participant could 
not reach a time of 3 minutes, the test was completed. 
 
A score was determined by calculating the total of the points generated during each level 
per arm.  The maximum number of points that can be achieved per level is 3 points.  For 
example, participant X completed level 1 and held onto the bags for 1 min and 30 seconds 
(right (R) arm) and 1 min 12 seconds (left (L) arm) during level 2.  Her score was: 
Level 1  =  (180 seconds achieved / 180 seconds maximum) x 3 
 =  3 points 
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R arm: 
Level 2 =  (90 seconds achieved / 180 seconds maximum) x 3 
= 1.5 points 
L arm: 
Level 2 =  (72 seconds achieved / 180 seconds maximum) x 3 
= 1.2 points 
Total score R arm: 
 =  4.5 
Total score L arm: 
 =  4.2 
 
The first 10 subjects of the control group performed the Bottle Test twice, after which we 
found the results to be repeatable.  Thereafter, the participants of the control group were 
only required to do the test once. Furthermore, the muscle action required resemble a biceps 
curl, which the majority of the controls had performed at some point in their lives.  All the 
participants of the control group advanced to stage 2 and 10 participants attempted stage 3 
for at least one arm.  Three individuals of this group wanted to repeat the test on the same 
day to try to better their score.  Their scores remained relatively unchanged also indicating 
repeatability in a healthy population, as shown below: 
 
Table i: 
Subject First attempt  
R arm 
Second attempt 
R arm 
First attempt  
L arm 
Second attempt 
L arm 
1 4.2 4.1 3.5 3.6 
2 3.8 3.7 3.7 3.6 
3 3.8 4.0 4.0 3.8 
Coefficient  
of Variation 
5.9% 5.3% 6.7% 3.1% 
  
Eight individuals of the HIV-infected participants that were recruited for this project took 
part in this test.  Five of these participants repeated the test again one week later.  On both 
occasions they were required to do the test twice (after resting for at least 1 hour in 
between).  The first attempt served as a familiarisation phase because the testing situation 
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was unfamiliar to the participants as confirmed by visual assessment.  The score of the 
second attempt was recorded as that week’s score. 
 
The results for the right arms are shown in Figure i.  The two graphs show a comparison 
between the results of the first and second week’s test scores with the test scores of the 
control group.  For both situations, the study group scores were significantly lower (p < 
0.05) than the scores of the control group (revealed by a Mann-Whitney U test).  However, 
the variability for the scores of the second week (Figure i Panel B) was remarkably less 
than for the first week (Figure i Panel B).  This probably indicates a learning-effect, since 
three of the participants (i.e. 60%) had higher scores for the second week’s test.  The Bland-
Altman plot shown in Figure ii provides additional evidence that a learning-effect occurred, 
since the upward trend to the right indicates that those participants with a low average score 
had improved scores for the second week.  The results for the left arm showed the same 
pattern (of lower subject group scores compared to the control group and less variability for 
the scores of the second week) as for the right arm (data not shown). 
 
Even though this new “Bottle Test” showed a learning effect, I believe it would be 
worthwhile to investigate its use in future since the study group had significantly lower 
scores than the control group.  It is possible that this difference reflects physical disability 
in the study group as a result of the HIV condition.  Therefore, I believe that this test (or a 
similar test) should be tested for validity and in a HIV infected population.  The test is very 
simple and doesn’t take a lot of time to perform.  The materials would also be very easy to 
acquire in a resource-poor setting.  I would suggest modifying the test to be validated so 
that it would include an activity that more closely reflects the participant’s daily lifestyle 
(like picking up a certain amount of bags with bottles and putting them onto a table of 
standard height and recording heart rate, time and rating of perceived exertion on a three-
level scale (easy, moderate and difficult)). 
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Figure i:  Week 1 (Panel A) and week 2 (Panel B) scores of the right arm of 
the study group (n = 5) compared to the control group (n = 76).  The box 
plots represent mean ± SE, while the whiskers indicate ± SD.  Extreme 
outliers are represented by a star ( ) while the middle points in the boxes 
signify the means.  
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Figure ii:  Bland-Altman plot of week 1 and week 2 right arm scores of the study group. 
 
 
Grip Strength Test: 
 
I also determined the grip strength with a grip dynamometer of both the study and the 
control group.  Reliability coefficients greater than 0.90 have been reported by others for 
this test of hand grip strength (Johnson & Nelson, 1979).   
 
The right hand grip strength measurements (in kg) of the two groups are shown in Figure 
iii.  Although the grip strength of 9 participants of the study group were determined, only 
the five that were included in the graphs of Figures i ii are included in this graph.  A 
comparison of the two groups revealed no significant difference with the Mann-Whitney-U 
test (the same was true for the left grip measurements (data not shown)). 
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Figure iii:  Right hand grip strength measurements of the control group (n = 
76) and the study group (n = 5).    The box plots represent mean ± SE, while 
the whiskers indicate ± SD.  Extreme outliers are represented by a star ( ) 
while the middle points in the boxes signify the means. 
 
Although is possible that the grip strength test is too insensitive to detect differences 
between a healthy group and a group affected by HIV, it is also possible that grip strength 
was unaffected in this study group.  A study with more participants and different tests of 
muscle function and strength may show differences between two such groups. 
 
Step test: 
 
It was decided that the existing cardiovascular fitness tests would be too difficult to 
administer in the environment that this particular project were done.  The commonly used 
walk tests (like the 12-minute Field Performance Test and the One-Mile Walk Test) require 
a considerable distance in a straight line or a large circular route (Maud & Foster, 1995).  
This was not available at some of the clinics where we performed measurements, and I also 
feared a high dropout rate from the study if I were to require them to do such tests.   
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Step tests would be easier to administer, since it doesn’t require a lot of space and a step 
would be easy to acquire or manufacture.  Unfortunately, step tests (like the Harvard Step 
Test and the OSU Step Test) require the participant to perform the exercise at a specified 
cadence with the aid of a metronome (Johnson & Nelson, 1979).  It quickly became 
apparent that this specific population group had great difficulty with this requirement since 
they lacked the coordination, skill and experience to perform a step test at a specified 
cadence.  Therefore, the self-paced step test developed by Petrella and colleagues (2001) 
was used.  The participants were required to step up and down two small steps 20 times.  
The time it took them to perform these 20 steps (T) as well as their heart rates immediately 
before and after the test were recorded.  Their resting heart rate was also recorded upon 
arrival at the clinic (after sitting for at least five minutes), before the step test was 
performed.  The percent of heart rate reserve (%HHR) was calculated for each test with the 
following formula: 
%HHR  = (post-step HR – HR at rest) / ((HRmax) – HR at rest)) x 100 
where HRmax = 220 - age 
 
Although seven participants of the study group performed this test at least once, only five 
of them repeated the test one week later.  As with the Bottle Test, they performed the test 
once to familiarize themselves with the protocol.  After a rest of at least one hour, they 
repeated the test.  The time and post-step heart rate of this second test was used as the score 
for the step test.  Bland-Altman plots were used to illustrate the %HHR  (Figure iv Panel 
A), post-step HR  (Figure iv Panel B) and the time it took the participant to perform 20 
steps  (Figure v). 
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Figure iv:  Percent of heart rate reserve and post-step heart rate for 5 
individuals of the study group. 
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Figure v:  The time it took the participant to perform 20 steps (T) for 5 
individuals of the study group. 
 
The differences between the %HRRs of week 1 and 2 were small (less than 10%) compared 
to the post-step HR.  The post-step HR was 24, 16 and 12 beats/min higher respectively for 
three participants during the second week compared to the first week.  Adjusting for resting 
HR by using the %HHR variable is therefore probably a better indicator of the individual 
heart rate response to activity.  It appears as though there is an upward trend for T (Figure 
v).  Although this sample is too small to make any conclusions from this graph, this could 
indicate that those with a high average time between the two weeks improved their time for 
the second week by completing the test in a shorter time.  This could then indicate a greater 
efficiency to perform the task and a possible learning-effect. 
 
Therefore, although the self-paced step test was very easy to perform in a clinical setting, 
further research is necessary to examine its validity and reliability in a South African 
population. 
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7.3. Appendix C 
 
Information sheets and consent forms: 
 
The University of Stellenbosch 
Department Physiological Sciences 
Subject Information Sheet 
 
Project Title:   
Body composition changes in HIV-positive females after initiating antiretroviral treatment, in 
comparison with CD4-count matched HIV-positive females not receiving ART. 
 
Coordinator:  
Prof K H Myburgh                    E-mail: khm@sun.ac.za 
Project researchers:  
Ms PC de Bruto (Master’s student)    Telephone:  (021) 808 4564 
(Supervisors: KH Myburgh, C Smith) 
Collaborator:  
Dr. Grobbelaar       Telephone: (021) 872 1711 
 
You are cordially invited to take part in a research study of which the aim is to monitor the quality of life 
and selected physiological parameters of HIV-positive people. 
 
Background 
 
There are various changes that can happen in the body as a result commencing antiretriviral 
treatment.  Fat distribution, body mass and metabolic changes can occur which may have an 
influence on quality of life and daily activities.   
 
During this study, certain parameters (CD4 count, body mass, body composition) will be assessed 
over a six month time period.  The aim of this assessment is to improve the researcher’s 
understanding of the course and impact of the disease and its treatment.  This knowledge is 
necessary to develop effective treatment principles and the information gained from the study will 
also be used to design subsequent studies.  The eventual aim is to develop practical programs with 
guidelines and recommendations which could help improve the quality of life of HIV positive people. 
 
Procedures 
 
The study will take place at the T. C. Newman Community Hospital under the supervision of Dr 
N.Grobbelaar.  
 
If you decide to take part in the study, you will have to visit the hospital at least eleven times.  Eight 
of these visits will coincide with your regular clinic visits and therefore you will only have to come to 
the clinic for three addisional visits.  You will receive compensation to the amount of sixty rand to 
compensate for the travel expenses of these three visits.   
 
If you decide to participate, the following measurements and procedures will be carried out at the 
clinic:  
 
 
1) Blood samples (one sample of 10 ml – approximately two teaspoons –  per occasion) will 
be taken after three months and after six months, by the medical doctor treating you. 
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2) Ten skinfold measurements will be taken in the following areas:  triceps (the back of the 
upper arm), subscapular (upper back), biceps (the front of the upper arm), iliac crest (just 
above the hip, on the side), supra-spinal (the side), abdominal (on the front), frontal thigh 
(the front of the upper leg), medial calve (the side of the calve), mid axial (on the side, 
between the arm and hip) and pectoral (on the front at the arm and chest junction).  These 
measurements are taken with a calliper, which “pinches” the skin slightly (no pain is felt with 
this procedure).  All these measurements will be taken in privacy.   
 
3) You will be weighed (with an electronic scale) and your height will be measured.  The 
circumferences of the upper arm, waist, hip, thigh and calve will also be measured. 
 
4) You will be asked to complete a quality of life questionnaire and you will be interviewed 
privately by the researcher to assist you in doing this.  The questionnaire will also be filled 
in at home at regular times.  The researcher will also ask questions about what you ate the 
previous day and your normal eating habits. All information gained will be regarded as 
highly confidential.   
 
5) You will be required to perform an exercise test on a treadmill.  The treadmill test begins by 
walking slowly.  The speed and gradient of the treadmill will be adjusted and you will be 
asked to exercise until you are close to total fatigue (about 90 % of your maximum ability, 
which we calculate).  This exercise test will take about ten to twenty minutes.  Your heart 
rate will be monitored before and during the exercise test, and a medical doctor will be on 
standby for the duration of the test.   
 
6) The researchers are interested in energy utilisation, daily activity level and metabolic 
tempo.  These factors will be measured with a heart rate monitor which you will wear for 
three days while you continue with your normal daily activities.  The heart rate monitor fits 
like a belt around the chest under your clothes and is not uncomfortable or even noticeble.   
 
In addition, if you agree to the procedure, Computed Tomography (CT) scans will be done at the 
Stellenbosch MediClinic (transport will be organised for you from the Paarl Hospital).  Scans of the 
abdomen and mid-thigh will be performed at Stellenbosch MediClinic by a radiographer and 
assessed by Dr R de Villiers (a radiologist).  Before doing the procedure, the radiologist will inform 
you of any side-effects or danger involved in having the scans taken of you.  From these scans the 
researchers will be able to view the relative amounts of muscle to fat mass in the scanned areas.   
 
The main advantage of taking part in this study, is that your body composition will be monitored 
regularly and free of charge.  At the end of the study, you will also receive information on how to 
change your eating habits to improve your health. The only disadvantage that we foresee, from 
participating in this study, is that you will have to make a few extra trips to the clinic and that your 
regular visits to the clinic may take longer than usual. The only risk is the very small dose of 
radiation which you will be subjected to when you go for a computed tomography scan, but this 
procedure is not a prerequesite for participation in the project, so you are free to decline taking part 
in this specific procedure. 
 
Blood samples will be collected by the medical staff from a vein in the forearm on two occasions, 
over and above the amount necessary for usual diagnosis and treatment of your illness.  Ten 
milliliter blood (which is approximately the same volume as two teaspoons) will be taken per 
occasion. The only side effect that can result from this procedure is occasionally a small bruise and 
tenderness. 
Fifty HIV-positive subjects will participate in this study.  
 
This project has been evaluated and approved by the Sub-Comittee C Ethics Committee of the 
University of Stellenbosch. 
 
Important: 
Stellenbosch University http://scholar.sun.ac.za
 105
 
You are free to withdraw from the study at any time without any explanation.  Your participation or 
lack of participation will in no way influence any other activities at the Hospital, and you will be 
treated without prejudice should you choose not to participate or to withdraw. Your withdrawal will 
not influence your future medical treatment in any way. 
 
All information regarding the tests, your illness and treatment thereof, will be kept confidential and 
publication or presentations of the results at conferences will not reveal your identity.  However, we 
will be pleased to discuss the results with you at the end of the study. 
 
Any further questions that you may have relating to the experiment will be answered in full by either 
the co-ordinator Prof KH Myburgh (021 808 3149) or the project investigator: Me PC de Bruto (021 
808 4564).  
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The University of Stellenbosch 
Department Physiological Sciences 
Consent Form 
 
Project Title:  
Body composition changes in HIV-positive females after initiating antiretroviral treatment, in 
comparison with CD4-count matched HIV-positive females not receiving ART. 
 
STATEMENT BY SUBJECT 
 
I, the undersigned......................................................................................... 
 
[ID .......................................] of .......................................................................................(address)  
 
A: I confirm that: 
 
1. I was invited to participate in the above-mentioned study that is being performed by the 
Department Physiological Sciences of the University of Stellenbosch.  
 
2. It has been explained to me that: 
 
2.1    The aims of this study will be to determine: 
Changes and associations between body mass and composition, immune 
parameters, physical activity and quality of life of HIV-positive subjects over the 
time period of six months.   
 
2.2 The following procedures will be followed: 
(a) Anthropometrical measurements at each occasion (eight times).  These will 
include skinfold thickness measurements with a Harpenden caliper, body and 
limb circumferences with a measuring tape and body mass on an electronic 
scale.  
(b) Heart rate will be measured with a heart rate monitor.  These measurements 
will be taken while lying down, sitting and standing as well as walking and slow 
running on a treadmill.   This protocol will be performed twice.  
(c) Ten milliliter blood will be taken on two occasions by a nurse or medical doctor. 
(d) A short and confidential questionnaire will be completed regularly at home.  
This takes about ten minutes per occasion. 
(e) A private and confidential interview will be conducted on three occasions.  
(f) Computed Tomography scans will be done on two occasions during which I will 
be exposed to minimal radiation, should I choose to take part in this particular 
procedure.  The radiation dose of each scan is approximately equivalent to that 
of one X-ray procedure.  This procedure is not a prerequisite for participation in 
the study. 
 
2.3 It is expected that this project would be completed on a total of 50 subjects. The project will 
ideally be completed over a period of 26 weeks.  There will be a total of at least 11 visits to 
the clinic over a period of 26 weeks.  Each visit will last about 1 to 3 hours. 
 
 
3. I have been informed of any possible side effects, discomfort or risk involved from my 
participation in this study.   
 
4. All the possible advantages of the study were explained to me.   
 
5. I have been informed that the information collected will be treated as confidential.  Every 
subject and his/her information will be represented by a code and thus no name will be 
associated with the individual results.   The results will be used for a scientific project, 
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publication and/or thesis, but my identity will not be revealed. 
 
6. Results of the entire project, as well as my own individual results, will be made available to me 
during/after completion of the project.  
 
7. I have been informed that I may refuse to participate in this study (also that I may discontinue 
participation at any time) and that such refusal or discontinuation would not be to the 
disadvantage of my future treatment at this institution. I also understand that the investigator 
may withdraw myself from the study should he/she feel that it would be in my best interest. 
 
8. No pressure has been placed on me to consent to my participation in this study and I 
understand that I may withdraw from the study at any time without being penalised. 
 
9. Participation in this study holds no additional costs for me. 
 
10. I understand that it may be known that HIV related research is conducted during the times  I 
visit the Hospital and although my HIV status will be known only to the researchers, I     
      understand that other people may associate me with the HIV related research. 
 
11. I will not hold Drs. Van Wageningen & Partners Inc. responsible for any loss or injury incurred 
as result of the CT scanning procedure, but I am aware that the University of Stellenbosch has 
insurance available should loss or injury occur. 
 
B:  I hereby freely consent to participate in the abovementioned study. 
 
 
 
Signed at ......................................................   on .............. 200.... 
 
 
 
 
.....................................................…………...   ............................... 
Subject signature or right thumb print     Witness 
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STATEMENT BY OR ON BEHALF OF INVESTIGATOR 
 
I, ............................................................................................, declare that: 
 
1. the information given in this document was explained to ………………………………. (Name of 
the patient) by me; 
 
2. I encouraged him/her/them to ask me any questions should there be anything that was unclear; 
 
3. that this conversation was conducted in Afrikaans/English and that no translator was used/ that 
this conversation was translated in Xhosa by 
  
 
 Dr/Mr/Mrs........................................................................... 
 
 
 
 Signed at ............................................................on  .................200.... 
 
 
 
 ...................................................... ................................. 
 Investigator/investigator’s representative          Witness 
 
 *  Delete if not relevant 
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Exercise Science Laboratory 
Department of Physiological Sciences 
University of Stellenbosch.  
 
Project Title:  
Body composition changes in HIV-positive females after initiating antiretroviral treatment, in 
comparison with CD4-count matched HIV-positive females not receiving ART. 
 
Statement of understanding: 
 
1. I have read and signed the attached informed consent. 
2. I understand I will receive the results of the research I requested. 
 
 
Signed at …………………………………..….. on ……………………..………...200 
…. 
(place)   (date) 
 
 
……………………………………………………
 ………………………………………….. 
Signature of patient/participant   Signature of witness 
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Die Universiteit van Stellenbosch 
Departement Fisiologiese Wetenskappe 
Proefpersoon Inligtingstuk  
 
Projektitel:   
Liggaamskomposisie veranderinge van MIV-positiewe vroue met die aanvang van antiretrovirale 
behandeling. 
 
Koördineerder:  Prof K H Myburgh                                         E-pos: khm@sun.ac.za 
Projek Navorsers:  
Ms PC de Bruto (Master’s student)    Telephone:  (021) 808 4564 
(Supervisors: KH Myburgh, C Smith) 
Medewerker:  
Dr. Grobbelaar       Telephone: (021) 872 1711 
 
U word vriendelik uitgenooi om deel te neem aan ‘n navorsingstudie waarvan die doel is om 
lewenskwaliteit en sekere fisiologiese parameters van MIV-positiewe persone te monitor. 
Agtergrond 
 
Daar verskeie liggaamlike veranderinge wat kan plaasvind met die aanvang van antiretrovirale 
behandeling. Liggaamsmassa en vetverspreiding kan verander, asook metaboliese veranderinge 
wat die lewenskwaliteit en daaglikse aktiwiteitsvlakke kan beïnvloed.   
 
Hierdie studie sal sekere parameters (byvoorbeeld; CD4-telling, massa en liggaamssamestelling 
(relatiewe vet en spiermassa)) monitor oor ses maande sodat ‘n beter begrip van die verloop en 
impak van die siekte en die behandeling daarvan verkry kan word.  Sulke kennis is nodig om 
effektiewe behandeling te ontwikkel en die verkrygde inligting sal gebruik word om verdere studies 
te ontwerp met die uiteindelike doel om suksesvolle programme te ontwikkel en te implimenteer om 
die lewenskwaliteit van MIV-positiewe persone te verbeter. 
 
Prosedures 
 
Die studie sal plaasvind by die T. C. Newman Hospitaal vir gemeenskapsgesondheid, onder toesig 
van Dr N.Grobbelaar. 
 
Daar sal van u verwag word om die hospitaal op minstens elf geleenthede te besoek.  Agt van 
hierdie besoeke sal met u gereelde kliniekbesoeke saamval, dus sal u slegs vir drie ekstra 
geleenthede na die kliniek toe kom.  U sal ‘n bedrag van sestig rand ontvang as vergoeding vir die 
reiskoste vir hierdie drie besoeke. 
 
Indien u besluit om deel te neem, sal die volgende metings en prosedures uitgevoer word by die 
kliniek: 
 
1) Bloedmonsters (een monster van 10 ml – ongeveer twee teelepels – per geleentheid) 
sal geneem word by die kliniek na drie maande en weer na ses maande.  
 
2) Tien velvoudiktes sal geneem word van die volgende areas:  triseps (boarm aan die 
agterkant), subskapulêr (boonste deel van die rug), biseps (boarm aan die voorkant), 
illiakkruin (net bo die heupe aan die sy), supraspinaal (die sy), abdominaal (aan die 
voorkant), frontale dy (voorkant van die bobeen), mediale kuit (die binnesy van die kuit), 
midaksilla (die sy, tussen die arm en heup) en pektoraal (aan die voorkant waar die arm 
en die bors bymekaarkom).  Die metings sal met ‘n kaliper geneem word, wat die vel 
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liggies “klem” en ‘n knypgevoel – sonder pyn – word ondervind.  Al hierdie metings sal 
in privaatheid geskied. 
 
3) Beide u liggaamsmassa (op ‘n elektroniese massaskaal) en u lengte sal gemeet word.  
Omtreksmetings (met ‘n maatband) sal geneem word van die boarm, middel, heup, 
bobeen en kuit). 
 
4) U sal gevra word om ‘n vraelys in te vul onder die toesig van een van die navorsers, 
asook by die huis op gereelde tye.  Die navorser sal in ‘n private onderhoud vir u vrae 
vra ten opsigte van wat u die vorige dag geëet het en wat u normaalweg eet.  Alle 
inligting verkry sal as hoogs vertroulik geag word.   
 
5) Daar sal van u verwag word om ‘n oefeningstoets te voltooi op ‘n trapmeul.  Die toets 
op die trapmeul en begin met ‘n stadige stap tempo.  Die spoed en helling van die 
trapmeul sal verstel word en daar sal van u verwag word om die toets te doen tot voor 
totale uitputting (ongeveer 90% van maksimale vermoë soos bereken deur die 
navorsers).  Die  oefentoets sal ongeveer tien tot twintig minute neem.  U harttempo sal 
geneem word voor en tydens die oefentoets.  ‘n Mediese dokter sal die toets bystaan. 
 
6) Die navorsers stel belang in u energieverbruik, daaglikse aktiwiteit en metaboliese 
tempo.  U sal ‘n harttempo monitor vir drie dae by die huis en werk moet dra, terwyl u 
voortgaan met normale daaglikse aktiwiteite.  Die harttempo monitor pas soos ‘n 
lyfband om die borskas onder die klere en is nie ongemaklik om te dra nie. 
 
Indien u bereid is, sal rekenaartomografie skandering gedoen word van die middel en bobeen.  Die 
prosedure word uitgevoer in Stellenbosch Medi-Clinic deur ‘n radiograaf en geëvalueer word deur 
Dr R de Villiers (‘n radioloog).  Die radiograaf sal u vooraf inlig omtrent enige newe-effekte of 
gevare betrokke by die skandering.  Hierdie skandering sal die navorsers in staat stel om die 
relatiewe spier- tot vetmassa in die betrokke areas waar te neem.  U sal (moontlik saam met 
ongeveer drie ander projekdeelnemers) na Medi-Clinic geneem word in ‘n bussie wat deur die 
Universiteit gereel word. 
 
Die grootste voordeel van deelname aan hierdie studie is dat u liggaamskomposisie gereeld 
gemonitor sal word teen geen persoonlike onkoste nie.  Aan die einde van die studie sal u inligting 
verkry omtrent u eetgewoontes en hoe u dit kan verander om u gesondheid te verbeter.  Die enigste 
nadeel wat ons voorsien van deelname aan hierdie studie, is dat u ‘n paar ekstra besoeke aan die 
kliniek sal moet maak en dat u gereelde besoeke aan die kliniek mootnlik effens langer sal neem as 
gewoonlik.  Die enigste risiko is dat u aan ‘n baie klein dosis bestraling blootgestel sal word tydens 
die neem van die rekenaartomografie skandering, maar hierdie prosedure is nie ‘n vereiste vir 
deelname aan die studie nie.  U kan dus kies om nie aan hierde spesifieke prosedure deel te neem 
nie. 
 
‘n Suster of mediese dokter sal bloed vanuit ‘n aar in u voorarm trek by twee geleenthede 
bykomend tot die geleenthede waanvan die doel diagnose en behandeling is.    Tien milliliter bloed 
(wat ongeveer gelykstaande is aan twee teelepels) sal getrek word per geleentheid.  Daar is geen 
newe-effekte nie, behalwe – in sommige gevalle – vir ‘n klein kneusplekkie.   
Vyftig MIV-positiewe proefpersone sal deelneem aan hierdie studie. 
 
Hierdie projek is deur die Subkomitee C Etiese komitee van die Universiteit van Stellenbosch 
geëvalueer en goedgekeur. 
 
Belangrik: 
 
U is vry om te enige tyd van die studie te onttrek sonder om ‘n verskoning te gee.  U sal sonder 
benadeling behandel word, indien u sou besluit om nie deel te neem nie of om te onttrek.  Indien u 
sou onttrek, sal dit nie enige ander aktiwiteite by die hospitaal beïnvloed nie.  Toekomstige mediese 
behandeling sal nie beïnvloed word indien u onttrek uit die studie nie. 
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Alle inligting aangaande die toetse, jou siekte en die behandeling daarvan, sal as vertroulik hanteer 
word, en u identiteit sal nie bekend gemaak word met publikasie of met die aanbieding van resultate 
nie. Nietemin sal ons graag die resultate met u bespreek aan die einde van die studie. 
 
Enige verdere vrae wat u in verband met die eksperiment mag hê, sal ten volle deur die 
koördineerder Prof K H Myburgh (021 808 3149) of projeknavorser: Me PC de Bruto (021 808 4564) 
beantwoord word.  
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Universiteit van Stellenbosch 
Departement Fisiologiese Wetenskappe 
Toestemmingsvorm 
 
Projektitel:  
Liggaamskomposisie veranderinge van MIV-positiewe vroue met die aanvang van antiretrovirale 
behandeling. 
 
VERKLARING DEUR DEELNEMER 
 
Ek, die ondergetekende,  ................................................................................................. 
 
 [ID .......................................] van ........................................................................................(adres) 
 
A: Ek bevestig dat: 
 
1. Ek uitgenooi is om deel te neem aan bogemelde navorsingsprojek wat deur die Departement 
Fisiologiese Wetenskappe van die Universiteit van Stellenbosch onderneem word. 
 
2. Daar aan my verduidelik is dat: 
 
2.1 Die doelwitte van hierdie studie is: 
   Om die veranderinge en onderlinge verwantskappe van liggaamsmassa,  
   liggaamssamestelling, immuun parameters, fisiese aktiwiteit en lewenskwaliteit  
  van MIV-positiewe deelnemers te monitor oor die tydperk van ses maande. 
 
2.2 Die volgende prosedures sal gevolg word: 
(a) Antropometriese metings by elke geleentheid (agt keer):  Velvoudiktes gemeet 
met ‘n diktemeter, liggaamsomtrekke met ‘n maatband, en liggaamsmassa met 
‘n elektroniese skaal. 
(b) Harttempo met ‘n harttempo monitor en uitgeasemde gasse met ‘n gasmasker 
gekoppel aan ‘n gas-analiseerder sal bepaal word.  Hierdie metings sal 
geneem word terwyl ‘n lêende, sittende, staande posisie ingeneem word, asook 
tydens loop en draf op ‘n trapmeul.  Hierdie protokol word twee keer uitgevoer.  
(c) Die trek van tien milliliter bloed by twee geleenhede deur ‘n suster of mediese 
dokter. 
(d) Die invul van ‘n kort en vertroulike vraelys by die huis op gereelde tye wat 
ongeveer tien minute sal neem. 
(e) ‘n Privaat en vertroulike onderhoud by drie geleenthede. 
(f) Twee geleenthede van rekenaartomografie skandering waartydens ek per 
geleentheid aan ‘n minimale bestralingsdosis, ongeveer gelykstaande aan die 
dosis van een X-straal prosedure, blootgestel sal word.  Hierdie prosedure is 
nie ‘n voorvereiste vir deelname aan die studie nie. 
 
2.3 Dit word verwag dat hierdie projek voltooi sal word met ‘n totaal van 50 proefpersone.  
 Ideaal gesien sal die projek oor ‘n periode van 26 weke afgehandel word.  Daar sal ‘n totaal 
van ten minste 11 besoeke aan die kliniek wees oor 'n periode van 26 weke.  Elke besoek sal 
ongeveer 1 tot 3 uur duur. 
 
3. Ek is ingelig oor enige moontlike newe-effekte, ongemak of nadelige effekte van deelname aan 
hierdie studie.   
 
4. Al die moontlike voordele van die studie is verduidelik.  
 
5. Inligting ingesamel in hierdie studie sal vertroulik wees.  Geen naam sal geassosieer word met 
individuele resultate nie, want elke proefpersoon sal deur ‘n nommer onbekend aan hulle 
verteenwoordig word.  Die resultate sal gebruik word vir ‘n wetenskaplike werkstuk, publikasie 
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of tesis, maar my identiteit sal nie bekend gemaak word nie. 
 
6. Tydens/na afhandeling van die projek sal resultate aan my beskikbaar gestel word aangaande 
die volledige projek, sowel as my eie individuele resultate sodra die projek voltooi is.  
 
7. Ek is meegedeel dat ek mag weier om deel te neem aan hierdie projek (asook dat ek te enige 
tyd deelname daaraan mag staak) en dat sodanige weiering of staking nie op enige manier my 
huidige/toekomstige behandeling by hierdie inrigting of die hospitaal sal benadeel nie. Ek 
verstaan ook dat die navorser my van die projek mag onttrek indien dit in my belang geag 
word. 
 
8. Daar geen dwang op my geplaas is om toe te stem tot my deelname aan hierdie projek nie en 
dat ek besef dat ek deelname te enige tyd mag staak sonder enige penalisasie. 
 
9. Deelname aan die projek geen addisionele koste vir my inhou nie. 
 
10.  Ek verstaan dat dit bekend mag wees dat daar MIV-verwante navorsing plaasvind in die  
 tye wat ek die kliniek besoek en selfs al is my MIV-status onbekend, begryp ek dat ander 
persone my mag assosieer met die MIV-verwante navorsing. 
 
11. Ek sal nie Drs. Van Wageningen & Vennote Ing. verantwoordelik hou vir enige verlies of 
besering as gevolg van die skandering prosedure nie.  Ek is wel daarvan bewus dat die 
Universiteit van Stellenbosch versekering beskikbaar het indien verlies of besering sou 
plaasvind. 
 
 
B Ek stem hiermee vrywillig in om deel te neem aan die bogemelde projek. 
 
 
Geteken te ...........................................................  op .............. 200.... 
 
 
 
 
 
..............................................................................   .............................. 
Deelnemer se handtekening of regter duimafdruk   Getuie 
 
 
 
 
VERKLARING DEUR OF NAMENS NAVORSER 
 
Ek, ............................................................................................, verklaar dat ek: 
 
1. die inligting vervat in hierdie dokument aan …………………………………..(Naam van die 
deelnemer) verduidelik het; 
 
2. hom/haar/hulle versoek het om vrae aan my te stel indien daar enigiets onduidelik was; 
 
3. dat hierdie gesprek in Afrikaans, Engels, plaasgevind het en dat geen tolk gebruik is nie/*dat 
hierdie gesprek in Xhosa getolk is deur 
  
 Dr/Mnr/Me........................................................................... 
 
 Geteken te ............................................................op  .................20.... 
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 ...................................................... ................................. 
 Navorser/Navorser se verteenwoordiger Getuie 
 
 *  Haal deur indien nie relevant nie 
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Projektitel:  
Liggaamskomposisie veranderinge van MIV-positiewe vroue met die aanvang van antiretrovirale 
behandeling. 
 
Verklaring van begrip: 
 
1. Ek het die aangehegte ingeligte toestemming gelees en geteken. 
2. Ek verstaan ek sal die resultate van die navorsing wat ek aangevra het ontvang. 
 
 
Geteken te ................................................................ op ................................... 20...... 
                                (plek)                                                                  (datum) 
 
 
................................................................. .......................................................... 
Handtekening van pasiënt/deelnemer             Handtekening van getuie 
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7.4. Appendix D 
 
Quality of life questionnaires: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Health Questionnaire 
 
     South African English version 
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By placing a tick in one box in each group below, please indicate which statements 
best describe your own state of health TODAY. 
 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
 
Compared with my general 
level of health over the past 12 months, 
my state of health today is: 
 
Better   PLEASE TICK 
Much the same  ONE 
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Worse  BOX 
 
 
 
 
 
 
To help people say how good or bad their state 
of health is, we have drawn a scale on which the 
best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale, in 
your opinion, how good or bad your own health 
is today. Please do this by drawing a line from 
the box below to whichever point on the scale 
indicates how good or bad your state of health is 
today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your own 
state of health 
today 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100
Worst 
imaginable 
state of health 
0 
Best  
imaginable 
state of health 
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Because all replies are anonymous, it will help us to understand your answers better 
if we have a little background data from everyone, as covered in the following 
questions. 
 
1. Have you experienced serious illness? Yes No 
  yourself   
  in your family   
  while caring for others   
 
2. What is your age in years ? 
 
3. Are you male or female? Male Female 
     
 
4. I smoke  
  I used to smoke  
  I have never smoked  
 
5. Do you now, or did you ever, work in Yes No 
 health services or social welfare?   
 
 If so, in what capacity? ............................................................................  
 
6. Which of the following best describes your main activity? 
  self employed  
  in formal employment   
  retired  
  homemaker/domestic worker  
  student  
  seeking work  
  other (please specify)  .............................................  
 
    
7. What was the highest grade that you attained at school? 
  Yes No 
8. Do you have a diploma or equivalent?   
 
 
9. If you know the area/suburb in which you stay, please write it 
here................................. 
 
PLEASE TICK 
APPROPRIATE 
BOXES 
PLEASE TICK 
APPROPRIATE 
BOX 
PLEASE TICK 
APPROPRIATE 
BOX 
PLEASE TICK 
APPROPRIATE 
BOX 
PLEASE TICK 
APPROPRIATE 
BOX 
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Gesondheidsvraelys 
  
Afrikaanse veergawe 
 (Afrikaans version) 
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Dui asseblief aan watter stellings u eie gesondheidstoestand vandag die beste 
beskryf deur ’n regmerkie in een blokkie by elkeen van die onderstaande 
groepe te maak. 
 
 
Beweeglikheid 
Ek het geen probleme om rond te loop nie  
Ek het sommige probleme om rond te loop  
Ek is beperk tot die bed  
 
Selfversorging 
Ek het geen probleme om myself te versorg nie  
Ek het sommige probleme om myself te was of aan te trek  
Ek is nie in staat om myself te was of aan te trek nie  
 
Gewone Aktiwiteite (bv. werk, studeer, huiswerk, familie- of 
ontspanningsaktiwiteite) 
Ek het geen probleme om my gewone aktiwiteite uit te voer nie  
Ek het sommige probleme om my gewone aktiwiteite uit te voer  
Ek is nie in staat om my gewone aktiwiteite uit te voer nie  
 
Pyn/ Ongemak 
Ek het geen pyn of ongemak nie  
Ek het matige pyn of ongemak  
Ek het uiterste pyn of ongemak  
 
Angstigheid/ Neerslagtigheid 
Ek is nie angstig of neerslagtig nie  
Ek is matig angstig of neerslagtig   
Ek is uiters angstig of neerslagtig  
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Om mense te help om te sê hoe goed of sleg hul 
gesondheidstoestand is, het ons ’n skaal (baie soos ’n 
termometer) geteken waarop die beste 
gesondheidstoestand wat u u kan verbeel, gemerk is 
met 100 en die slegste gesondheidstoestand wat u u 
kan verbeel, gemerk is met 0. 
 
Ons wil graag hê dat u op hierdie skaal aandui hoe 
goed of sleg u eie gesondheid vandag na u mening is. 
Doen dit asseblief deur ’n streep te trek vanaf die 
blokkie hieronder (waar dit sê: “u eie 
gesondheidstoestand vandag”) tot by enige punt op 
die skaal wat aandui hoe goed of sleg u 
gesondheidstoestand vandag is. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U eie 
gesondheids- 
toestand 
vandag 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100
Slegste  
denkbare 
gesondheids- 
d
0 
Beste 
denkbare 
gesondheids-
d
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Omdat alle antwoorde naamloos is, sal dit ons help om u antwoorde beter te 
verstaan indien ons ’n bietjie agtergrondinligting oor almal het, soos in die 
volgende vrae gedek. 
 
1. Het u ernstige siekte ondervind?  Ja  Nee 
in uself          
in u familie         
in die versorging van andere       
 
2. Wat is u ouderdom in jare? 
 
3. Is u:      Manlik  Vroulik 
      
 
4. Is u: 
’n huidige roker     
’n voormalige roker     
iemand wat nog nooit gerook het nie  
 
5. Werk u nou, of het u ooit in die   Ja  Nee 
gesondheids- of maatskaplike dienste gewerk?   
Indien wel, in watter hoedanigheid? …………………………………. 
 
6. Watter van die volgende beskryf   
u hoofaktiwiteit die beste? 
  in diens wees of vir uself werk  
  afgetree     
  huiswerk     
  student     
  soek werk     
  ander (spesifiseer asseblief)  ……………………... 
 
7. Het u onderwys voortgegaan na die  Ja  Nee 
minimum skoolverlatersouderdom     
(15 jaar oud / Graad 9 / Standerd 7)? 
 
8. Het u ’n graad of ’n diploma?   Ja  Nee 
         
Indien u u poskode ken, sal u dit asseblief hier neerskryf     
      
MERK 
 ASSEBLIEF  
TOEPASLIKE  
BLOKKIES 
MERK 
 ASSEBLIEF  
TOEPASLIKE  
BLOKKIE 
MERK 
 ASSEBLIEF  
TOEPASLIKE  
BLOKKIE
MERK 
 ASSEBLIEF  
TOEPASLIKE  
BLOKKIE 
MERK 
 ASSEBLIEF  
TOEPASLIKE  
BLOKKIE 
MERK 
 ASSEBLIEF  
TOEPASLIKE  
BLOKKIE 
MERK 
 ASSEBLIEF  
TOEPASLIKE  
BLOKKIE 
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EQ - 5D 
 
 
Iphepha lemibuzo ngezempilo 
 
 
(Inguqulelo yesiXhosa saseMzantsi Afrika 
Xhosa Version) 
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Beka uphawu kwibhokisi ibenye kwiqela ngalinye echaza imeko yempilo yakho namhlanje, 
kwezi bhokisi zilandelayo. 
 
Musa ukuphawula ngaphezulu kwebhokisi enye kwiqela ngalinye. 
 
Ukuhamba 
Andinangxaki zokuhamba   
Ndinazo ingxakana zokuhamba   
Ndingumlwelwe obopheleleke ebhedini   
 
Ukuzinonophela isiqu 
Andinangxaki zokuzinonophela                                                                         
Ndinazo ingxakana zokuhlamba okanye ukuzinxibisa                                      
Andikwazi ukuzihlamba okanye ukuzinxibisa                                                    
 
Izinto zesiqhelo (Umsebenzi, Ukufunda izifundo 
Umsebenzi wasekhaya, Usapho, Ezolonwabo) 
Andinangxaki nokuzenzela izinto zesiqhelo                                          
Ndinazo iingxakana zokuzenzela izinto zesiqhelo                             
Andikwazi kuzenzela izinto zesiqhelo                                                   
  
 
Iintlungu / Ukungaziva kakuhle 
Andinazintlungu okanye ukungaziva kakuhle   
Ndinentlungwana okanye ukungaziva kakuhle okungephi   
Ndinentlungu ezigqithileyo okanye ukungaziva kakuhle okugqithileyo   
 
Ukuxhalaba / Ukudakumba 
Andinaxhala okanye andidakumbanga                              
Ndibuxhalaba okanye ndibudakumba                               
Ndixhalabe gqitha okanye ndidakumbe gqitha                                                 
 
Xa ndithelekisa umgangatho wobunjani 
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bempilo yam jikelele kwezi nyanga  
zili-12 zidlulileyo imeko yempilo yam 
namhlanje: 
 
Ingcono           Phawula
  
Ibufana  ibhokisana 
Imandundu  efanelekileyo 
 
 
Ukunceda abantu ukuze baxele okokuba 
imeko yabo yempilo intle okanye imandundu 
na sizobe isikali (esifana nethemometha). 
Eyona meko entle yempilo iphawulwe ngo-
100, eyona meko imandundu iphawulwe ngo-
0. 
 
Singathanda ubonise kwesi sikali ngokoluvo lwakho 
ukuba impilo yakho intle okanye imandundu 
kangakanani namhlanje. 
Nceda wenze oku ngokuzoba umgca osuka 
ebhokisini engezantsi ukuya kulo ndawo 
esikalini ibonisa ukuba imeko yempilo yakho 
intle okanye imbi kangakanani namhlanje. 
 
 
 
 
 
                                                                                                        > 
 
                                                                          
  
 
 
 
 
          Ibhokisi 
Imeko yempilo 
yakho 
namhlanje
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100
Eyona meko 
imandundu 
yempilo 
k i ik l l
0 
Eyona meko entle 
yempilo onokuyiqikelela
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Njemgoko kunganyanzelekanga ukuba ubhale igama lakho, kodwa ke kuyakunsinceda 
siqonde ngcono iimpemdulo ukuba sinolwazana lwemvelaphi kulowo nalowo umntu 
njengoko zichatshazelwe kule mibuzo ilandelayo 
 
 
1.   Ukhe wabanamava okugula kakhulu na?               Ewe           Hayi 
  Wena   
  Kusapho lwakho   
  Xa ukhathalele abanye   
 
 
2. Mingaphi iminyaka yakho? 
 
 
3. U-  Yindoda Libhinqa 
     
 
 
4.  Uyatshaya  
  Wawutshaya  
  Ungumntu ongazange atshaye  
 
 
5. Usebenza, okanye ukhe wasebenza Ewe Hayi 
       kwiinkonzo zezempilo okanye ezentlalontle?                       
    
 
 Ubusenzani?............................................................................................  
 
 
6.    Koku kulandelayo kokuphi okuchaza ngcono  
       okwenzayo? 
  Uyaphangela okanye uyazisebenzela  
  Udla umhlalaphantsi  
  Umsebenzi wasekhaya  
  Umfundi  
  Ufuna umsebenzi  
  Okunye (Chaza)   
 
 
7. Leliphi ibanga ofikelele kulo esikolweni?………………………………………..  
    
 
8. Unesidanga okanye i-diploma Ewe Hayi 
     
 
9.    Ukuba uyayazi ikhowudi yeposi yakho nceda uyibhale apha  
   
 
Phawula iibhokisana 
ezifanelekileyo 
Phawula ibhokisana 
efanelekileyo 
Phawula ibhokisana 
efanelekileyo 
Phawula ibhokisana 
efanelekileyo 
Phawula ibhokisana 
efanelekileyo 
 
Phawula ibhokisana 
efanelekileyo 
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Modified QoL questionnaire - English 
 1
By placing a tick in one box in each group below, please indicate 
which statements best describe your own state of health TODAY. 
 
  Mobility  
F  &  I have no problems in walking about  
F  , I have some problems in walking about  
F  '  I am confined to bed  
 
  Self-Care 
F  &  I have no problems with self-care  
F  , I have some problems washing or dressing myself  
F  '  I am unable to wash or dress myself  
 
 
  Usual Activities 
         (e.g. work, study, housework, family or 
      leisure activities) 
F  &  I have no problems with performing my usual activities  
F  , I have some problems with performing my usual activities  
F  '  I am unable to perform my usual activities  
 
 
  Pain/Discomfort 
F  &  I have no pain or discomfort
F  , I have moderate pain or discomfort
F  '  I have extreme pain or discomfort
 
 
  Anxiety/Depression 
F  &  I am not anxious or depressed
F  , I am moderately anxious or depressed
F  '  I am extremely anxious or depressed
 
 
 
 
 
 
 
 
 
 
 
 
9 0
8 0
7 0
6 0
5 0
4 0
3 0
2 0
1 0
100
          Worst 
imaginable 
state of health
0
Best 
imaginable 
state of health
1
2
3 
4
5
6
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Dui asseblief aan watter stellings u eie 
gesondheidstoestand VANDAG die beste beskryf deur ’n 
regmerkie in een blokkie by elkeen van die onderstaande 
groepe te maak. 
 
 
  Beweeglikheid  
F  &  Ek het geen probleme om rond te loop nie  
F  , Ek het sommige probleme om rond te loop  
F  '  Ek is beperk tot die bed  
 
 
  Selfversorging 
F  &  Ek het geen probleme om  
           myself te versorg nie  
F  , Ek het sommige probleme om  
           myself te was of aan te trek  
F  '  Ek is nie in staat om  
           myself te was of aan te trek nie  
 
 
 
 
 
  Gewone Aktiwiteite  
          (bv. werk, studeer, huiswerk, familie- of     
           ontspanningsaktiwiteite) 
F  &  Ek het geen probleme  
           om my gewone aktiwiteite uit te voer nie
F  , Ek het sommige probleme om  
           my gewone aktiwiteite uit te voer
F  '  Ek is nie in staat om  
           my gewone aktiwiteite uit te voer nie
 
 
  Pyn/ Ongemak 
F  &  Ek het geen pyn of ongemak nie
F  , Ek het matige pyn of ongemak
F  '  Ek het uiterste pyn of ongemak
 
 
  Angstigheid/ Neerslagtigheid 
F  &  Ek is nie angstig of neerslagtig nie
F  , Ek is matig angstig of neerslagtig 
F  '  Ek is uiters angstig of neerslagtig
 
9 0
8 0
7 0
6 0
5 0
4 0
3 0
2 0
1 0
100
Slegste denkbare 
gesondheidstoestand 
0
Beste denkbare 
gesondheidstoestand 
1 
2 
3
4
5
6 
Modified QoL questionnaire - Afrikaans 
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 1
Beka uphawu kwibhokisi ibenye kwiqela ngalinye echaza 
imeko yempilo yakho namhlanje, kwezi bhokisi 
zilandelayo. 
 
Musa ukuphawula ngaphezulu kwebhokisi enye kwiqela 
ngalinye. 
  Ukuhamba 
F  &  Andinangxaki zokuhamba  
F  , Ndinazo ingxakana zokuhamba  
F  '  Ndingumlwelwe obopheleleke ebhedini  
 
 
  Ukuzinonophela isiqu 
F  &  Andinangxaki zokuzinonophela                                                                        
F  , Ndinazo ingxakana zokuhlamba okanye ukuzinxibisa                                     
F  '  Andikwazi ukuzihlamba okanye ukuzinxibisa                                                  
  
 
  Izinto zesiqhelo 
          (Umsebenzi, Ukufunda izifundo 
       Umsebenzi wasekhaya, Usapho, Ezolonwabo) 
F  &  Andinangxaki nokuzenzela izinto zesiqhelo   
F  , Ndinazo iingxakana zokuzenzela izinto zesiqhelo  
F  '  Andikwazi kuzenzela izinto zesiqhelo  
 
 
  Iintlungu / Ukungaziva kakuhle 
F  &  Andinazintlungu okanye  
          ukungaziva kakuhle
F  , Ndinentlungwana okanye  
          ukungaziva kakuhle okungephi
F  '  Ndinentlungu ezigqithileyo okanye  
          ukungaziva kakuhle okugqithileyo
 
 
  Ukuxhalaba / Ukudakumba 
F  &  Andinaxhala okanye  
          andidakumbanga
F  , Ndibuxhalaba okanye  
          ndibudakumba
F  '  Ndixhalabe gqitha okanye  
          ndidakumbe gqitha                                               
 
 
 
 
 
 
 
9 0
8 0
7 0
6 0
5 0
4 0
3 0
2 0
1 0
100
Eyona meko 
imandundu 
yempilo
0
Eyona meko 
entle yempilo 
onokuyiqikelela
1 
2 
3 
4
5
6 
Modified QoL questionnaire - Xhosa 
 132
7.5. Appendix E 
 
The individual changes of ART participants for some variables that relate to nutritional status 
are shown in the graphs below. 
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Figure vi:  Individual data-points of %IBW and %IAC for the ART group at baseline, short 
term and long-term time points.   
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Figure vii:  Upper arm fat (UAFA) and muscle (UAMA) areas as individual data-points for 
the ART group at baseline, short term and long-term time points.   
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